Archive for January, 2018

$VSQTF New Strategic Initiative Related to FansUnite Media, Inc.

VANCOUVER, British Columbia, Jan. 31, 2018 — Victory Square Technologies Inc. (“Victory Square” or the “Company“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that, as part of the Company’s long-term strategy to maximize shareholder value, the board of directors has approved a strategic initiative to unlock the intrinsic value of its wholly owned portfolio subsidiary, FansUnite Media Inc. (“FansUnite“) by contemplating a distribution of a portion of the common shares currently held to shareholders of Victory Square. Victory Square will evaluate, consider and assess the mechanism by which to effect such distribution on a tax efficient and financially prudent basis, with the aim of ultimately capitalizing FansUnite into a stand-alone publicly listed entity, which is anticipated to occur later this year.

FansUnite is developing a new social sports platform using blockchain technology. Blockchain technology and the inherent security it provides will enable FansUnite to develop a reliable, transparent platform that is expected to become a standard amongst betting platforms around the world. The newly created FansUnite Token has been developed as the currency to be used across the platform, harnessing the benefits of blockchain technology to avoid payment problems associated with legacy gambling, providing freedom of choice over betting markets, ensuring betting arrangements are honoured exactly as entered, and providing stable value and low costs. FansUnite is progressing with licensing and regulatory arrangements and expects to launch this new platform in 2018.

Shafin Tejani, Chief Executive Officer of Victory Square, commented: “The objective of the contemplated distribution is to provide shareholders with a significant stake in FansUnite as it progresses towards the launch of its new sports betting platform, pursues capital raising and explores opportunities to become a stand-alone publicly traded company. This will enable the capital markets to appropriately value one of our portfolio investments while we continue to concentrate on our core business as a venture builder and technology incubator.”

Subject to all requisite regulatory approvals, the mechanism, timing and quantum of any such future distribution will be subject to the determination of the Company’s board of directors, in its sole discretion, taking into account, among other things, liquidity, financial condition, corporate strategy, tax implications, market trends and other capital market considerations. There is no assurance that any such distribution will be made in a timely manner or at all, or that Victory Square will complete the planned distribution of FansUnite common shares within the anticipated timeframe or at all.

For further information about the Company, please contact:

Investor Relations Contact – Prit Singh
Email: ir@victorysquare.com
Telephone: 905-510-7636

Media Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066

This news release should not be construed as an offer or sale or the solicitation of an offer to buy of securities in the United States or to, or for the account or benefit of, U.S. persons and no securities may be offered, distributed or sold in the United States absent registration or an exemption from registration. 

ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.

ABOUT FANSUNITE MEDIA INC.
Operating as a division of Victory Square Technologies Inc., FansUnite operates a social sports data platform (www.fansunite.com) which was launched by three sports fans who wanted to take sports back to the global community of fans that fuel the industry. With a free virtual currency, members make their fantasy sports picks with zero monetary risk and are able to track their selections with the proprietary PickTracker. FansUnite.com offers a full-unedited look into the picking history of individual players and their peers. FansUnite Consensus literally allows members to see what the crowd is saying.

FORWARD-LOOKING INFORMATION
This news release includes forward-looking information within the meaning of Canadian securities legislation concerning the business of Victory Square, including expectations relating to the future business and operational plans of FansUnite, the launch of its platform and FansUnite Tokens, as well as obtaining applicable licensing and regulatory approvals. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including that FansUnite will be able to obtain all regulatory and licensing approvals in order to launch its platform as designed and developed, and that it will be able to meet its operational objectives within the anticipated timeframe. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on forward-looking information and Victory Square can give no assurance that such information will prove to be correct. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements, or those of FansUnite, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information, including those risks and uncertainties contained in the Company’s publicly filed documents and materials. Forward-looking information contained in this news release is made as of the date of this news release, and Victory Square disclaims any obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Wednesday, January 31st, 2018 Uncategorized Comments Off on $VSQTF New Strategic Initiative Related to FansUnite Media, Inc.

$ETST Enters New Stage of Cannabis Industry Growth

January 31, 2018

  • Cannabis industry expected to reach $24.5 billion in sales within four years
  • Company expanding into Canada ahead of expected nationwide legalization
  • Medical diagnostic device set for clinical tests to validate detection of STDs

With the sunny investment disposition toward marijuana and blockchain-related industries carrying over from late 2017’s marketplace into the new year (http://nnw.fm/3Kzml), Florida-based Earth Science Tech, Inc. (OTC: ETST) is optimistic about its ability to serve the medical and recreational needs of a growing population of cannabis users. The biotechnology company has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high-grade hemp CBD oil, placed its cannabidiol (CBD) food products in retail stores throughout the country, established a non-profit foundation to help underprivileged patients use its products and acquired Quebec, Canada-based Canna Inno Laboratories Inc. in a bid to expand into that country as it prepares to legalize the recreational use of marijuana on a national basis later this year.

Earth Science Tech, Inc. announced in May 2014 that it was entering the legal cannabis and medical marijuana industry as a natural progression of its mission to deliver wellness and alternative medicine options to American consumers. In the nearly four years since, a growing number of states have legalized medicinal and recreational uses for marijuana derivatives as popular sentiment has shifted toward acceptance of the drug despite its continued classification as a controlled substance by the federal government. The revolution in Canada that is expected to result in full legalization this summer has outpaced U.S. attitudes and provided a near-neighbor alternative for U.S. businesses that continue to encounter market obstacles at home.

Variances in forecasts about the market potential for the legal cannabis industry are measured in billions of dollars nowadays; cannabis industry analysts Arcview Market Research, in partnership with BDS Analytics, predicts that the market will reach $24.5 billion in sales within the next three to four years with a 28 percent CAGR that follows on a 33 percent increase between 2016 and 2017 despite ongoing federal prohibition (http://nnw.fm/pEAM5). As this market potential grows, Earth Science Tech is working to uplist under the OTCQB’s regulations for new Tier II Regulation A+ companies, with hopes for SEC approval by March.

The proposed uplisting will underpin efforts to raise an additional $4 million in operating capital so the company can complete planned projects advancing its brand in the United States and Canada. In December, Earth Science Tech announced a CBD product revamp and brand education strategy (http://nnw.fm/3nYfW) that it expected to launch by the end of January, along with a renewed push for major donors to help its non-profit foundation and a collaboration with a start-up accelerator in Canada to help it ramp up its brand awareness.

In February, the company plans to begin a nine-month series of human clinical trials on its new CBD formulation, which is designed to decrease cravings and the negative effects of withdrawal in addicts. If the trials prove successful, the product is set to launch in 2019 as a new addition to the stable of Earth Science Tech patent-pending offerings.

“We look to hit the ground running in 2018 with all we have lined-up in the first quarter,” president, director and COO Nickolas Tabraue stated in a news release. “We have other exciting discussions that are progressing well, and we will share those once any material developments have been finalized. Our story and vision will be seen very soon and we greatly appreciate all who have believed in us since the beginning.”

Another aspect of Earth Science Tech’s mission is to develop low-cost, noninvasive home-use diagnostic tools for sexually transmitted infections and/or diseases. The company’s first medical device has been labeled MSN-2, which is set for clinical tests under an agreement with Laboratories BNK Canada to ensure the device meets regulatory requirements as part of the company’s bid to meet the specific needs of women. Earth Science Tech has already established the MSN-2 device’s ability to detect chlamydia, and it now aims to validate similar results for gonorrhea, another sexually transmitted disease that can have permanent consequences for patients if untreated. The company also plans to add testing to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. The diagnostic testing market for STDs is expected to grow to $108 billion by 2019, according to Transparency Market Research.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, January 31st, 2018 Uncategorized Comments Off on $ETST Enters New Stage of Cannabis Industry Growth

$CIIX NetworkNewsWire Publication on Emerging Leaders in Blockchain and Cryptos

NEW YORK, Jan. 31, 2018 – via NetworkWire – NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ChineseInvestors.com, Inc. (OTCQB:CIIX), a client of NNW recognizing unprecedented opportunities in the U.S. cannabis industry and laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

To view the full publication, titled “Sino Adoption of Blockchain Technologies, Cryptocurrencies on Horizon,” visit: LINK

This move will enable CIIX to allocate its resources toward educating the Chinese public regarding cryptocurrencies and blockchain technologies, along with related marketing and operational efforts.

Recognizing the Chinese community’s mounting interest in cryptocurrency, CIIX currently broadcasts a daily newscast, “Bitcoin MultiMillionaire,” operates its free bitcoin Chinese language education site, www.newcoins168.com, and recently reached agreement to host a bitcoin ATM in the lobby of its headquarters in San Gabriel, California.

About ChineseInvestors.com

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products. For more information visit www.ChineseInvestors.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Wednesday, January 31st, 2018 Uncategorized Comments Off on $CIIX NetworkNewsWire Publication on Emerging Leaders in Blockchain and Cryptos

$STLHF Commences Resource Definition in Southern Arkansas

VANCOUVER, British Columbia, Jan. 30, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to announce that the Company has commenced detailed resource definition work at its recently optioned 33,000 acres of brine leases, located in a highly prospective area of the Smackover Formation in Southern Arkansas, USA.  This work integrates collection of new data from current well infrastructure, with a large amount of already-available, high quality, geological, geophysical and geochemical data.

The lease area has been historically drilled for oil and gas exploration, and approximately 256 exploration and production wells have been completed in the Smackover Formation in or immediately adjacent to Standard’s new lease area (almost 3,000 wells have been drilled in southern Arkansas and provide excellent data to support interpretation in Standard’s lease zone).  All of these 256 wells have geological logs, and all can be used to constrain the top of the Smackover Formation’s brine-bearing zone.  In addition, a sub-set of 30 wells has full core reports that provide detailed data, and downhole geophysical logs that include formation resistivity and porosity data.  A further sub-set of 15 wells also has full core samples available from the Smackover Formation, these cores (available from the Arkansas Geological Survey core library) can be sent for additional laboratory testing to further refine porosity estimates for the Smackover resource zone in Standard’s lease area.

In addition, Standard Lithium has retained Shreveport, Louisiana based Hill Geophysical Consulting to provide key geological interpretation of the lease area.  The Principal, Kevin Hill, has several decades of experience gathering and interpreting geophysical data from the Southern Arkansas area, and has been instrumental in identifying structures, lithological/porosity variations and new resource zones in the Smackover Formation throughout Standard’s area of interest.  Of key importance is that Hill Geophysical have licensed access to over 320 km (200 miles) of high resolution 2D-seismic line data that have been collected in Standard Lithium’s new lease area, and these lines fully image the total thickness of the Smackover Formation and fine-scale structures and lithology variations that are present therein.  Hill Geophysical Consulting is in the process of integrating the 256 well logs from the lease area into the 2D-seismic data, and is working towards producing a 3D-block model of the Smackover Formation underlying Standard’s leases.

Standard is also in advanced discussions with oil and gas producers with open, unused Smackover wells in and immediately adjacent to the new lease area to gather new, high quality lithium brine samples from the key brine production zones in the Smackover Formation.  The new samples will supplement the extensive historical geochemical brine data available from the area of interest.

President and Chief Operating Officer, Dr. Andy Robinson commented, “One of the reasons that the Company aggressively pursued this lease package in the Smackover Formation was because we knew that not only was there was a wealth of high quality data already available to define the resource, but also several key professionals who could help us integrate and interpret those data.  We’re now at the point where we can very quickly work through the resource assessment process and identify where we need to collect any additional data to ensure a robust and comprehensive understanding of the lithium brine resource potential.  Execution of this very fast resource assessment process is part of Standard’s corporate strategy to move large potential resources as quickly towards production as we can.

Quality Assurance

Raymond Spanjers, Certified Professional Geologist (SME No. 3041730), is a qualified person as defined by NI 43-101, and has supervised the preparation of the scientific and technical information that forms the basis for this news release.  Mr. Spanjers is not independent of the Company as he is an officer in his role as Vice President, Exploration and Development.

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills.  The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities.  The Company is also commencing resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

For further information, contact Anthony Alvaro at (604) 240 4793

On behalf of the Board,

Standard Lithium Ltd.

Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information.  These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information.  Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties.  Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

Readers are cautioned that a “Qualified Person” (as that term is defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects) has not done sufficient work to specify any mineral resource or reserve on the Properties.

Tuesday, January 30th, 2018 Uncategorized Comments Off on $STLHF Commences Resource Definition in Southern Arkansas

$DJACF & Tokyo Smoke Close Merger and Launch Hiku Brands

Hiku becomes Canada’s first retail & brand-focused licensed cannabis producer. Fully vertically integrated operations positions Hiku for superior margins in Canadian adult-use recreational market.  

(KELOWNA, BC and TORONTO, ON), January 30, 2018 – Hiku Brands Company Ltd. (“Hiku” or the “Company”) today announced the successful completion of the merger between DOJA Cannabis Company Limited (CSE:DOJA) (“DOJA”) and TS Brandco Holdings Inc. (“Tokyo Smoke”) (the “Merger”), creating Hiku, Canada’s first premium cannabis brand house with vertically integrated operations.

Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing portfolio of premium cannabis lifestyle brands – DOJA, Tokyo Smoke and Van der Pop. It is anticipated that Hiku’s common shares  (the “Hiku Shares”) will commence trading on the Canadian Stock Exchange (the “Exchange”) under the ticker symbol HIKU on or about January 31, 2018.

Today, I am proud to stand with a team of incredibly talented and thoughtful business partners as we launch Hiku and create the first great cannabis brand house.” said Alan Gertner, Chief Executive Officer of Hiku. “A brand house, because cannabis is a consumer product, one that we believe can change the world. At Hiku, we look forward to playing a major role in driving this incredible industry forward.”

Highlights of Hiku

  • Portfolio of iconic cannabis brands: Hiku’s brand portfolio contains three of the most recognized, engaging and authentic cannabis brands in Canada: DOJA, Tokyo Smoke and Van der Pop. It is anticipated that a tailored assortment of adult-use, premium cannabis products will be retailed under each brand across Canada
  • National retail footprint: Hiku operates six Tokyo Smoke cafés and one DOJA café in Ontario, Alberta and British Columbia (collectively “Brand Stores”). Brand Stores sell coffee, legal cannabis accessories and clothing, creating a unique retail experience optimized to build brand awareness, develop community, educate consumers and serve potentially as consumption lounges in locations where permitted
  • Retail dispensing stores: Hiku will prioritize retail expansion in provinces allowing private cannabis retail (“Dispensing Stores”), with plans to open Dispensing Stores in 2018. Vertically integrated operations will allow Hiku to better control in-store customer experience, offering consistent, high quality, and exclusive products and enable higher margins
  • Handcrafted cannabis production: Hiku’s premium cannabis is grown in BC’s Okanagan Valley. Hiku prides itself on taking a handcrafted artisanal approach to trimming and curing, aimed at producing the finest cannabis. Annual licensed production capacity of 660 kgs per year expected to increase organically to over 5,000 kgs per year by the end 2018
  • Secured supply agreements: Ground-breaking supply partnerships with Aphria Inc. (“Aphria“) (TSX: APH) (OTCQB: APHQF) and WeedMD Inc. (TSXV: WMD) (“WeedMD”) ensure Hiku’s brands will be able to scale in 2018 and beyond. These partnerships bring unparalleled experience in cannabis production and ensure secured supply for what is expected to be a supply-constrained market at the onset of legalization
  • Strong financial position: A strategic financing of $12.5 million led by Aphria bolsters Hiku’s cash position to approximately $32.6 millio
  • Robust pipeline of growth opportunities: Hiku will look to make strategic investments and acquisitions to grow its brand portfolio, retail footprint, and scale production capacity
  • Industry leading management team: Hiku is led by visionaries Alan Gertner, CEO of Hiku, and Trent Kitsch, President of Hiku. Hiku’s management team has breadth and depth of expertise, with a proven track record of building and scaling businesses, including SAXX Underwear and a $100 million+ business at Google. The supporting team brings expertise from retail, cannabis, finance, design, marketing and creative fields

For more information on Hiku please visit our website at www.hiku.com.

Transaction Summary

The Merger was effected by way of a three-cornered amalgamation whereby DOJA’s wholly-owned subsidiary amalgamated with Tokyo Smoke and DOJA acquired all of the issued and outstanding securities of Tokyo Smoke.  As part of the Merger, holders of Tokyo Smoke shares received 13 common Hiku Shares for each Tokyo Smoke share held and outstanding Tokyo Smoke convertible securities were exchanged, subject to adjustment, into substantially similar convertible securities of Hiku.  In connection with the completion of the Merger, DOJA changed its name to “Hiku Brands Company Ltd.”.

In connection with the completion of the Merger, an aggregate of 55,971,058 Hiku Shares were issued to holders of Tokyo Smoke shares.

Hiku Management

In connection with the completion of the Merger, Hiku welcomes three new members to its board of directors. Alan Gertner, Chief Executive Officer of Hiku will join Hiku’s board along with co-founder of Tokyo Smoke, Lorne Gertner and Charles Broderick.

Each of Jeff Barber, Stewart Thornhill and Patrick Brauckmann have resigned as directors of the Company and Hiku thanks them for their service.

In addition, Trent Kitsch and Ryan Foreman resigned as the Company’s Chief Executive Officer and President, respectively.  Going forward, Mr. Kitsch will serve as Hiku’s President. Alan Gertner has been appointed Hiku’s Chief Executive Officer.

Strategic Financing

Effective immediately prior to the completion of the Merger, 8,992,807 subscription receipts previously issued by the Company (see press release of January 9, 2018) automatically converted into units of the Company (the “Units”).  Each Unit being comprised of one Hiku Share and one common share purchase warrant (a “Warrant“). Each Warrant entitles the holder to acquire one additional Hiku Share until January 30, 2020 at an exercise price of $2.10 per share; provided, however, that if the volume weighted average price of the Hiku Shares on the Exchange is equal to or greater than $3.05 for any twenty (20) consecutive trading days, Hiku may, upon providing written notice to the holders of the Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

Hiku anticipates entering into a supply agreement with Aphria (the “Supply Agreement”) to secure cannabis concentrate supply for Hiku’s premium brand portfolio.  As partial consideration for entering in the Supply Agreement and fulfilling its obligations thereunder, Hiku will issue 799,361 Units to Aphria.

Financial and Legal Advisors

Stoic Advisory Inc. and INFOR Financial Inc. acted as financial advisors and Wildeboer Dellelce LLP acted as legal advisor to Tokyo Smoke.

Pushor Mitchell LLP acted as legal advisor to DOJA.

About Hiku

Hiku is focused on handcrafted cannabis production, immersive retail experiences, and building a portfolio of iconic, engaging cannabis lifestyle brands. Hiku is differentiated as the only Canadian craft cannabis producer with a significant national retail footprint and a growing brand house including premium cannabis lifestyle brands DOJA, Tokyo Smoke, and Van der Pop.

Hiku’s wholly owned subsidiary, DOJA Cannabis Ltd., is a federally licensed producer pursuant to the ACMPR, owning two production facilities in the heart of British Columbia’s Okanagan Valley. The company operates a network of retail stores selling coffee, clothing and curated accessories, across British Columbia, Alberta and Ontario.

For more information, please visit www.hiku.com

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About WeedMD

WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and is awaiting its second-site cultivation license for its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. The Company is focused on providing medical cannabis to the long-term care, assisted living and seniors’ markets in Canada through its specialized and comprehensive platform. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

Early Warning Disclosure Pursuant to National Instrument 62-103

In connection with the Merger, 2441124 Ontario Inc. (a corporation jointly owned and controlled by Alan Gertner and Lorne Gertner), Alan Gertner and Lorne Gertner acquired ownership, control or direction over securities of Hiku requiring disclosure pursuant to the early warning requirements of applicable securities laws. Immediately prior to completion of the Merger, neither 2441124 Ontario Inc. nor Lorne Gertner had ownership of, or exercised control or direction over, any voting or equity securities of Hiku. Prior to the completion of the Merger, Alan Gertner held options to purchase 100,000 Hiku Shares at a price of $0.95 per Hiku Share (“Alan’s Existing Options”), representing approximately 0.15% of the issued and outstanding Hiku Shares on a partially diluted basis (i.e. assuming the exercise of only Alan’s Existing Options).

Pursuant to the Merger, 2441124 Ontario Inc. acquired ownership of 19,771,713 Hiku Shares, representing approximately 15.17% of the issued and outstanding Hiku Shares. Pursuant to the Merger, Alan Gertner acquired options to purchase 363,779 Hiku Shares at a price of $0.19 per Hiku Share (together with Alan’s Existing Options, “Alan’s Options”) and Lorne Gertner acquired options to purchase 71,279 at a price of $0.19 per Hiku Share (“Lorne’s Options”). In connection with the Merger, Hill & Gertner Capital Corp., a corporation jointly owned and controlled by Lorne Gertner and another shareholder, acquired ownership of 318,916 Hiku Shares.

Following the completion of the Merger, Alan Gertner indirectly owns and controls 19,771,713 Hiku Shares as a result of his joint ownership and control of 2441124 Ontario Inc., representing approximately 15.17% of the issued and outstanding Hiku Shares. In addition, if Alan Gertner were to exercise all of Alan’s Options, he would obtain ownership and control over an additional 463,779 Hiku Shares, which when aggregated with the other Hiku Shares indirectly owned or controlled by Alan Gertner, would total 20,235,492 Hiku Shares, representing approximately 15.47% of the issued and outstanding Hiku Shares on a partially diluted basis (i.e. assuming the exercise of only Alan’s Options).

Following the completion of the Merger, Lorne Gertner indirectly owns and controls 20,090,629 Hiku Shares as a result of his joint ownership and control of each of 2441124 Ontario Inc. and Hill & Gertner Capital Corp., representing approximately 15.41% of the issued and outstanding Hiku Shares. In addition, if Lorne Gertner were to exercise all of Lorne’s Options, he would obtain ownership and control over an additional 71,279 Hiku Shares, which when aggregated with the other Hiku Shares indirectly owned or controlled by Lorne Gertner, would total 20,161,908 Hiku Shares, representing approximately 15.46% of the issued and outstanding Hiku Shares on a partially diluted basis (i.e. assuming the exercise of only Lorne’s Options).

Other than Alan’s Existing Options, each of 2441124 Ontario Inc., Alan Gertner and Lorne Gertner acquired their respective securities of Hiku in connection with the Merger. The Hiku Shares acquired by 2441124 Ontario Inc. and Hill & Gertner Capital Corp. are subject to a contractual hold period as negotiated between Hiku and Tokyo Smoke (the “Hold Period”), pursuant to which 25% of such Hiku Shares will become tradeable on each of the days that is 4.5 months, 9 months, 13.5 months and 18 months following the closing of the Merger, respectively. 2441124 Ontario Inc., Alan Gertner and Lorne Gertner each may, from time to time, take such actions in respect of their respective holdings in securities of Hiku as they may deem appropriate, in light of the circumstances then existing, including the purchase of additional Hiku Shares or other securities of Hiku or the disposition of all or a portion of the their respective securityholdings in Hiku, subject in each case to applicable securities laws, the Hold Period and the terms of such securities, as applicable.

An early warning report will be filed by 2441124 Ontario Inc., Alan Gertner and Lorne Gertner in accordance with applicable securities laws. To obtain a copy of the early warning report, please contact Alan Gertner at 647-347-6653.

Statement Regarding Forward-Looking Information

This news release contains statements that constitute “forward-looking statements”.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Hiku’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements in this document include statements regarding Hiku’s expectations regarding its future cash position, its plans to expand its cannabis production capacity, the change in its ticker symbol to HIKU and the date of commencement of trading under such ticker symbol, its plans to retail premium cannabis products across Canada, its plans to use Brand Stores as consumption lounges, its plans to prioritize retail expansion and to open Dispensing Stores, the expectation that Dispensing Stores will generate higher margins, its expectation that the market will be supply-constrained at the onset of legalization of recreational cannabis use, the composition of the board of directors and management team of Hiku, the expectation that Hiku will enter into the Supply Agreement, regulatory approvals and other statements that are not historical facts.  By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others:

  • Hiku may require financing from time to time in order to continue its operations; financing may not be available when needed or on  terms and conditions acceptable to Hiku;
  • new laws or regulations could adversely affect Hiku’s business and results of operations;
  • Hiku or its suppliers may experience crop failures which could adversely affect its business and results of operations;
  • competitive forces within the cannabis industry could adversely impact Hiku’s business and results of operations; and
  • stock markets have experienced volatility that often has been unrelated to the performance of companies. These fluctuations may adversely affect the price of the Company’s securities regardless of its operating performance.

When relying on the Hiku’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and risks and other uncertainties and potential events. Hiku has assumed that the material factors referred to in the previous paragraphs will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. Hiku undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS NEWS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS NEWS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.

The Canadian Securities Exchange has not approved nor disapproved the contents of this news release.

For more information:

Abigail Van Den Broek

abby@abigailv.ca

416-799-8510

Tuesday, January 30th, 2018 Uncategorized Comments Off on $DJACF & Tokyo Smoke Close Merger and Launch Hiku Brands

$CIIX Sino Adoption of Blockchain Technologies, Cryptocurrencies on Horizon

January 30, 2018

NetworkNewsWire Editorial Coverage: The widespread adoption of cryptocurrencies and blockchain technologies is all but inevitable.  The technologies demonstrate numerous consumer and commercial advantages, particularly in logistics, international trade, and even food-safety and product anti-counterfeiting drives. As global and online commerce expands, so does the need for streamlined verification of product quality, delivery and payments, a few of the many capabilities offered by blockchain technology. An emerging leader in this space is ChineseInvestors.com (CIIX) (CIIX Profile), which, among other cryptocurrency-related endeavors, recently opened a bitcoin ATM at its U.S. headquarters in California. Other companies operating in the cryptocurrency and blockchain space include MGT Capital Investments, Inc. (MGTI), Bitcoin Investment Trust (GBTC), LongFin Corp. (LFIN) and Overstock.com, Inc. (OSTK).

China’s Growing Middle and Upper Classes

Many experts see China as the next big frontier for cryptocurrencies and blockchain technologies. Of course, the big fundamental is that the world’s second-largest economy is now China, topped only by the United States. Moreover, at current annual economic growth rates of just under 7%, China’s gross domestic product (GDP) should about double in the next 10 to 12 years. Given the size of its population, China will eventually eclipse the United States as the world’s largest economy.

The rapid emergence of Chinese middle- and upper-classes creates a large pool of consumers who want assurance of product provenance and delivery, as well as an avalanche of new investors who will seek to place a portion of their portfolios into cryptocurrencies – not only as a pure investment, but to ease investment into other asset classes, and to effect transactions.

“If you carry the trends forward, it is probable that Chinese investors will be the richest group in the world within 20 years or less,” ChineseInvestors.com (CIIX) CEO Warren Wang recently stated.

Since its inception in 1999, CIIX has become a leading financial information website for Chinese-speaking investors in the United States and China. To sharpen its focus on cryptocurrencies and financial education, the company has decided spin-off its CBD Biotechnology and ChineseHempOil.com subsidiaries (http://nnw.fm/sri0Y), which it plans to register as a separate publicly traded company.

This move will enable CIIX to allocate it resources toward educating the Chinese public regarding cryptocurrencies and blockchain technologies, along with related marketing and operational efforts.

Recognizing the Chinese community’s mounting interest in cryptocurrency, CIIX currently broadcasts a daily newscast, “Bitcoin MultiMillionaire,” operates its free bitcoin Chinese language education site, www.newcoins168.com, and recently reached agreement to host a bitcoin ATM in the lobby of its headquarters in San Gabriel, California.

Sino wealth creates prospects for investment products

“The signs of accumulating capital in China are obvious, from soaring condo prices in major cities such as Shanghai, to top dollar paid for authentic Sino antiquities. The Hong Kong Hang Seng Index, which is heavily tied to mainland-listed companies and the Sino economy, is up 50% in the last 12 months,” observes Wang. “Labor is also becoming more expensive—so much so, that some manufacturers are already off-shoring to cheaper platforms, such as in Southeast Asia.”

As incomes rise, Chinese citizens “can accumulate savings, as they have long wanted to. China has a high savings rate,” explains Wang. “The prospects for investment products that are properly positioned in China are extraordinarily bright.”

Beijing ban

However, Chinese authorities in a series of rules stretching back into early 2017 have made it increasingly difficult for Sino residents to trade in cryptocurrencies, including a ban in September on exchanges trading in bitcoin.  Some of China’s largest cryptocurrency exchanges, including OKCoin and Huobi, halted trading between bitcoin and yuan, awaiting more clarity from financial regulators.

The China-based BTCC was the world’s oldest bitcoin exchange, but closed down last year under pressure from Chinese authorities. New ICOs are also banned in China.

China Investors Adapt

“Despite regulations, Chinese investors have demonstrated they want to bitcoin and other cryptocurrencies to be part of their assets,” observes Wang.

Many Chinese investors are selling and buying cryptocurrencies through unregulated, over-the-counter exchanges, after the official ban on conventional exchanges from trading in the digital currencies. Notably, the unregulated trading is still legal.

“The present environment for cryptocurrencies in China requires for even more-knowledgeable participation by Chinese consumers and investors, and thus even a greater need for education and insightful commentary,” noted Wang. “Evolving environments usually offer more challenges but more opportunities that static situations.”

Wang advised industry entrepreneurs to be patient with Chinese investors while Sino residents learn about digital wallet management and the processes for trading in bitcoin and other cryptocurrencies. He also expressed confidence that China will organize a regulated market for cryptocurrency trading in the future.

In addition, Chinese monetary officials appear to be migrating to a national cryptocurrency system, the details of which have yet to be worked out, or at least made public. A researcher at the People’s Bank of China (which is the nation’s central bank and monetary authority) told a public forum in November that it is “crucial” that the country organizes an official central bank-issued cryptocurrency at an early date.

In the past, Beijing has often undertaken initiatives in commerce, but then increasingly relied on the private-sector to bring visions to fruition. Indeed, speaking at the international World Economic Forum in January 25, Liu He, regarded as President Xi Jinping’s top economic planner, told the global financial elite in Davos that China would be even more engaged in economic “reforms” going forward, usually an expression that means increased reliance on market forces.  If and when the People’s Bank of China implements a national cryptocurrency, it too may invite increasing participation from the private-sector to make such a currency as efficient and universal as possible. To date, mainland officials have only run trials of a prototype national cryptocurrency.

Meanwhile, the private sector is evolving networks of talent and financiers to help the blockchain industry develop in China. For example, in 2015 the China-based Fenbushi Venture Capital, with Vitalek Butarin, the founder of Ethereum, as adviser.  Fenbushi’s general partner is Feng Xiao, founder of Bosera Asset Management, one of the first and largest mutual funds in China. The use of blockchain technology to identify counterfeit goods, and prevent their online dissemination, may be one of the first widely adopted uses of the immutable ledgers enabled by blockchain systems.

“Whatever the shape of the China economy going forward, cryptocurrency and blockchain technologies will play a key and growing role,” said Wang. “There will be a vast and increasing need for informed reporting and education in these topics, for consumers, investors and entrepreneurs.”

Wang added that there is tremendous opportunity for ChineseInvestors.com to bring added revenue and profitability to its shareholders as the huge Far East investment community seeks timely insights into the presently volatile market of bitcoin and other cryptocurrencies. Wang urged entrepreneurs and venture capitalists to be patient in China, both with the population and the government. “Throughout history, in every nation, the best technologies are ultimately adopted,” advised Wang. “Beijing wants the China economy to modernize, to become integrated with the global economy. Cryptocurrencies and blockchain technologies will help with those goals.”

Potential Blockchain Comparables

MGT Capital Investments (MGTI) operates subsidiaries developing a portfolio of cybersecurity technologies. The company address cyber-threats through protection technologies for mobile and personal tech devices, as well as corporate networks. MGTI also operates a bitcoin mining operation.

Bitcoin Investment Trust (GBTC) is a U.S.-based open-ended grantor trust, sponsored by Grayscale Investments, that invests exclusively in bitcoin, which of course, is the pioneering use blockchain technology to verify ownership and confirm transactions. Bitcoin Investment Trust is the first publicly quoted bitcoin investment enterprise, with its shares the first securities to be solely invested in and deriving value from the price of bitcoin. BIT enables investors to gain exposure to bitcoins through a traditional and liquid investment vehicle, without the challenges of buying, storing and safekeeping bitcoins. BIT, along with bitcoin futures-trading recently undertaken by Cboe Global Markets (CBOE) and the CME Group (CME), thus broadens the market and reduces the risk of investing in, owning and or using bitcoins in transactions.

LongFin (LFIN) is working to connect 70 FX and spot exchanges with 300 banks through its electronic market platform. Earlier this month, LongFin announced that its Ziddu Smart Contracts are commercially available on the Ethereum blockchain. Longfin contends Ziddu.com is currently the only venue for decentralized smart contracts. The Ziddu contracts allow for an open but immutable ledger, decentralized verification, and transparent execution. Ziddu also offers micro-finance and lending against collateralized warehouse receipts.

As one of the earliest retailers to accept bitcoin payments, online retailer Overstock.com (OSTK) in December 2017 launched a $250 million initial coin offering (“ICO”). Company CEO Patrick Byrne told CNNMoney he may even consider selling off the better-known online retail business to focus on the 10 blockchain companies it owns.

For more information on ChineseInvestors.com, please visit: ChineseInvestors.com (CIIX)

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, January 30th, 2018 Uncategorized Comments Off on $CIIX Sino Adoption of Blockchain Technologies, Cryptocurrencies on Horizon

$MNLO Closes IPO, Full Exercise of Underwriters’ Option

REDWOOD CITY, Calif., Jan. 29, 2018 — Menlo Therapeutics Inc. (NASDAQ:MNLO) today announced the closing of the Company’s initial public offering of 8,050,000 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,050,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $136.9 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by Menlo. Menlo’s common stock is listed on The NASDAQ Global Select Market under the ticker symbol “MNLO.”

Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities, LLC are acting as joint book running managers for the proposed offering. JMP Securities is acting as the lead manager for this offering.

A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on January 24, 2018.  The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at 1-877-821-7388; or by email at Prospectus_Department@Jefferies.com; Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402; by phone at 1-800-503-4611; or by email at prospectus@pjc.com; or Guggenheim Securities, LLC, Attention: Capital Markets Syndicate, 330 Madison Avenue, 8th Floor, New York, New York 10017 or by email at gsprospectusdelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Menlo Therapeutics

Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough. The company has initiated a broad clinical development program for serlopitant including Phase 2 studies for the treatment of pruritus associated with atopic dermatitis, pruritus associated with psoriasis, and refractory chronic cough, and expects to start Phase 3 trials for the treatment of pruritus associated with prurigo nodularis in the first half of 2018. Menlo Therapeutics has worldwide rights to serlopitant, excluding Japan where Menlo Therapeutics has licensed serlopitant to JT Torii.

Contact for Menlo Therapeutics: media@menlotx.com

Investor Contact: patti.bank@westwicke.com

Monday, January 29th, 2018 Uncategorized Comments Off on $MNLO Closes IPO, Full Exercise of Underwriters’ Option

$IMMR Reaches Global Settlement With $AAPL

Immersion Corporation (Nasdaq: IMMR), the leading developer and licensor of touch feedback technology, today announced that the Company has entered into settlement and license agreements with Apple, the terms of which are confidential.

About Immersion Corporation

Immersion is the leading innovator of touch feedback technology, also known as haptics. The company provides technology solutions for creating immersive and realistic experiences that enhance digital interactions by engaging users’ sense of touch. With more than 2,600 issued or pending patents, Immersion’s technology has been adopted in more than 3 billion digital devices, and provides haptics in mobile, automotive, advertising, gaming, medical and consumer electronics products. Immersion is headquartered in San Jose, California with offices worldwide. Learn more at www.immersion.com.

Immersion and the Immersion logo are trademarks of Immersion Corporation in the United States and other countries.

(IMMR – C)

 

Immersion Corporation
Nancy Erba, 408-350-8850
Chief Financial Officer
nerba@immersion.com
or
The Blueshirt Group
Jennifer Jarman, +1-415-217-5866
jennifer@blueshirtgroup.com

Monday, January 29th, 2018 Uncategorized Comments Off on $IMMR Reaches Global Settlement With $AAPL

$PBIO to Host Webinar Update for Investors

Company to Discuss Expected Impact on 2018 Revenue from Recent Product Enhancements, New Field Salesforce, Technology Asset Acquisition, and Newly Issued Patents

SOUTH EASTON, MA / January 29, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, President and CEO of PBI, will host a webinar update and live Q&A session for investors on Tuesday, January 30, 2018, at 4:10 pm EST. The webinar will include discussions on enhancements made to products in the Company’s core Research Products & Services business segment, the Company’s new field salesforce, the acquisition of all assets of BaroFold Corporation, and the issuance of patents on the Company’s cutting-edge Ultra Shear Technology (“UST”) platform. The Company will also offer a brief outlook for the 2018 fiscal year.

To view the webinar, please visit: https://www.redchip.com/events/17/pressure-biosciences-webinar

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

http://www.pressurebiosciences.com

Forward-Looking Statements

Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President & CEO, PBI
(T) 508-230-1828

Victor Roberts, RedChip Companies
(T) 407-644-4256 (111)
victor@redchip.com

Monday, January 29th, 2018 Uncategorized Comments Off on $PBIO to Host Webinar Update for Investors

$IGC Exciting Outlook 2018, Near-term Clinical Trials, Long-term Blockchain Tech

SEATTLE, WA, Jan. 29, 2018 — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc.(NYSE: IGC) and its shift into the cannabis industry. India Globalization operates a legacy infrastructure business that consists of heavy equipment rental, real estate management, and commodities trading, but its primary focus has shifted to medical cannabis in recent years and more recently to blockchain.  Investors interested in the space may want to take a closer look given its near-term clinical trials and long-term focus on developing blockchain technologies to solve critical issues facing the industry.

SeeThruEquity, a leading independent equity research firm focused on emerging public companies, issued an update note on January 8, 2018 and raised its price target on the stock to $2.00. This represents a significant 100%+ premium to the current market price of $0.97 per share.

Near-term Cannabinoid Pipeline

India Globalization Capital is a leading cannabis-based pharmaceutical company with a pipeline of products designed to improve the lives of patients battling Alzheimer’s disease, Parkinson’s disease, chronic pain, post-traumatic stress disorder, and eating disorders. Under the guidance of its Science Officer Dr. Jagadeesh Rao, Ph.D., the company is working on four different proprietary cannabinoid-based products targeting serious medical conditions.

  • Hyalolex – A proprietary cannabinoid formulation that includes low doses of THC and is intended to disrupt the buildup of amyloid beta plaque and alleviate some of the worst symptoms of Alzheimer’s disease.
  • Serosapse – A cannabinoid formulation targeting certain end points of Parkinson’s disease.
  • Caesafin – A phytocannabinoid therapy designed to alleviate seizures in cats and dogs.
  • Natrinol – A cannabinoid formulation designed for AIDS and cancer induced nausea and vomiting, as well as for appetite stimulation.

These four products are divided into seven different clinical programs with some pre-clinical and clinical trials expected to begin later this year:

IGC-501 — Neuropathic Pain — Adults — N/A

IGC-502 — Seizures — Veterinary — 2019

IGC-503 — Refractory Epilepsy — Adults — N/A

IGC-504 — Eating Disorders — Adults & Veterinary — 2018

IGC-505 — Seizures — Veterinary — N/A

IGC-506 — Eating Disorders — Adults & Veterinary — N/A

IGC-ADI — Alzheimer’s Disease — Adults — 2018

The most critical and near-term clinical trials would be for Hyalolex for the treatment of patients with Alzheimer’s disease. This therapy is based on research conducted by Dr. Chuanhai Cao, Associate Professor of Pharmacy at the University of South Florida, who has already demonstrated signs of efficacy in both in vivo and in vitro studies. Alzheimer’s disease is the most expensive disease to treat at nearly $260 billion per year, according to the Alzheimer’s Association, surpassing both heart disease and cancer. These costs are expected to balloon to $758 billion by 2050, which creates an enormous need for effective treatment options.

In addition to FDA clinical trials, the company expects to license its formulation technology for distribution as a Complementary and Alternative Medicine (CAM) through licensed medical cannabis dispensaries in key medical markets in the United States and Canada. Management expects to bring the medication to patients in select markets in early 2018, with subsequent expansion to additional U.S. states dependent on product procurement and associated compliance achievement. These activities could generate nearer-term revenue as clinical trials progress, which creates both short- and long-term value for shareholders.

Expanding into Blockchain Tech

India Globalization Capital recently announced that it would leverage its existing team of technology and health care experts to develop methods utilizing blockchain technology in areas such as product identification assurance. In particular, the team hopes to address a recent study that was published showing that nearly 70 percent of all cannabidiol (CBD) products sold online are either over or under labeled, which can be dangerous for consumers. Blockchain technology involves the creation of a verifiable digital ledger to avoid these problems.

“We understand the unique challenges facing the cannabis industry and believe that our team has the expertise to be the first to create meaningful solutions to address these issues using distributed ledgers inherent in blockchain technology,” said CEO Ram Mukunda. “As we work to develop blockchain in the rollout of Hyalolex, our goal would be to establish a universal cannabis platform applicable to solving multiple industry challenges.”

Initially, the company hopes to apply the blockchain technology to its rollout of Hyalolex. The move could create a valuable proof of concept prior to a rollout of the platform as an independent product that could be licensed within the industry. The goal would be to address issues like transactional difficulties, inadequate product labeling, product identification assurance, and product origin assurance for patients, regulators, and dispensaries.

Please follow the link to read the full article: http://www.cannabisfn.com/india-globalization-exciting-outlook-2018-near-term-clinical-trials-long-term-blockchain-tech/

For more information about the company visit the company’s website at www.igcinc.us.

For more information on its cannabis pharmaceutical products visit: www.igcpharma.com

For more information on Hyalolex visit: www.hyalolex.com

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

 

CFN Media
Frank Lane
2063697050
flane@cannabisfn.com
Monday, January 29th, 2018 Uncategorized Comments Off on $IGC Exciting Outlook 2018, Near-term Clinical Trials, Long-term Blockchain Tech

$ETST Inks Deal to Develop its MSN-2 Medical Device

January 29, 2018

  • Deal includes design, development and clinical testing of MSN-2 medical device-related services
  • Study-specific testing will center on sexually-transmitted infections (“STIs”)
  • World Health Organization estimates that 357 million new STIs are contracted yearly
  • Global diagnostic market for STIs projected at more than $200 billion by 2022

Earth Science Tech, Inc. (OTC: ETST), an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development, has signed a deal with a private laboratory for clinical studies related to its MSN-2 medical device. The partnership, announced in a January 9 news release (http://cnw.fm/9pAPP), brings together ETST’s wholly owned subsidiary, Earth Science Pharmaceutical, Inc., and Laboratories BNK Canada Inc. (www.LaboBNK.com), in a partnership with significant clinical goals.

“We are on the cusp of making tremendous progress in our clinical trial efforts,” Dr. Michel Aubé, CEO and CSO of ETST, stated in a news release. “Our partnership with BNK will allow us to leverage the expertise of R&D veterans of many years, which will help us move more quickly, develop more products, cut costs, and ultimately, treat more patients.”

BNK’s team of professional scientists from pharmaceutical, clinical research and hospital settings will assist ETST in the design, development and validation of testing methods that meet all regulatory requirements. In addition, BNK will assist with the determination and development of study-specific tests for ETST clinical projects and bring expertise in clinical research project management to ensure that all trials run smoothly. This expertise will help the company maintain efficiency and reduce research and development costs.

Both companies are expressing an urgency for the work to quickly move forward. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and it is working to validate similar results for gonorrhea. ETST also plans to add testing for trichomoniasis, as well as a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. Both are highly infectious sexually transmitted infections.

The World Health Organization estimates that there are an estimated 357 million new sexually transmitted infections each year that often carry permanent consequences for patients and society at large (http://cnw.fm/sZh91). The World Health Organization now recommends that all pregnant women be tested for chlamydia, which has created a very large testing market. This partnership with BNK is expected to help ETST increase its total attainable market in this space and allow the company to commercialize its new testing services more quickly.

“We are extremely happy to be working with Earth Science Tech on their MSN-2 project,” said Dr. Gilles Brisson, BNK president and scientific director. “This project has the potential to completely change the way we look at sampling for STI infections and is certainly a positive development in women’s health around the world. This collaboration will be the fundamental driver for the success of this project.”

In a new study by Grand View Research Inc., the global market for STI diagnostic devices is forecast to be more than $200 billion by 2022 (http://cnw.fm/z0apU). Key findings of the report state that, in 2014, chlamydia testing accounted for 34 percent of the market, with laboratory testing devices dominating and generating over $67 billion.

ETST now has the laboratory partner needed to support the company’s research and development efforts, along with the commercialization of its MSN-2 medical device, which has been specifically developed to support women’s health and the related molecular diagnostics to which women desperately need access, Aubé said.

“STIs can have severe consequences. It is very important to prevent spreading” he said. “For example, we can cure the Chlamydia infections, but any permanent damage done by the long-term infection will not be repaired.”

Earth Science Pharmaceutical, Inc. is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted illnesses.

For more information, visit the company’s website at www.EarthSciencePharmaceutical.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Monday, January 29th, 2018 Uncategorized Comments Off on $ETST Inks Deal to Develop its MSN-2 Medical Device

$KTOS Opens Oklahoma Design and Production Facilities Due to Demand for UAV Drones

Recent Large New Multi-Year Program Wins and Expected Future Tactical Drone System Production Drives Requirements for Expanded Facilities

SAN DIEGO, Jan. 26, 2018 — Kratos Defense & Security Solutions, Inc. (Nasdaq:KTOS), a leading National Security Solutions provider, announced today that the company’s Unmanned Systems Division is opening administrative and engineering offices and production facilities in Oklahoma City to accommodate expected increased demand for high performance, jet powered unmanned aerial tactical and target drone systems.

“Advanced military target drones with fighter-like performance have been the mainstay of our company and we have come to dominate that market as our customers are replacing their drone fleets with the latest technology, and as a result, orders have increased substantially,” said Steve Fendley, President of Kratos Unmanned Systems Division.

Referring to a recent Aviation Week and Space Technology article entitled, “Kratos Expands Target Drone Business,” which discusses, “Target Drones with Fighter Like Performance;” Fendley commented, “This is Kratos’ niche in the unmanned aircraft arena, and the article reports that more than 1,500 MQM-107 target aircraft were produced. Our BQM-167, already in production with the USAF since the mid 2000’s has now also been selected as the replacement for the MQM-107 and begins production for the U.S. Army this year. We see the potential as even greater than for the heritage 107s with the increased capabilities our 167 offers. In addition, our tactical UAS drone systems have generated significant interest and we expect to be focusing these efforts and ramping up production of these tactical aircraft in Oklahoma, which has a highly educated and technical workforce, offers a cost-effective business and family environment, and is a great place for employees to live.”

Earlier this month Kratos announced a $23 million unmanned aerial drone system production award from an unnamed customer and a $93 million contract to supply target drones to the Army. This most recent contract makes Kratos the sole supplier of jet-powered, sub-scale target drones to all branches of the U.S. military. Kratos’ unmanned target drones recently participated in Exercise Formidable Shield 2017, a live-fire integrated air and missile defense (IAMD) exercise conducted by Naval Striking and Support Forces NATO on behalf of U.S. 6th Fleet.

Kratos is also currently under contract to develop and demonstrate high performance tactical drone systems that act as a loyal wingman to manned fighter aircraft or can operate independently. The company’s Mako tactical unmanned aerial drone system completed its initial successful test flights in 2015 and most recently participated in a major military exercise, with additional flights planned for this year. Kratos is scheduled to deliver its next generation tactical drone, the Valkyrie, in 2018.

“We are both honored and privileged to be here today in the great State of Oklahoma,” said Eric DeMarco, President and CEO of Kratos. “Kratos is focused on delivering technology and products for greater effectiveness at an affordable cost for our customers, and our new facility in Oklahoma City is another step forward in the successful execution of that strategy.” Mr. DeMarco continued with, “U.S. Senator James Inhofe (R-OK), U.S. Congressman Steve Russell (R-OK), and Governor Mary Fallin were each instrumental in introducing Kratos to the state of Oklahoma and showcasing the resources available as well as describing and demonstrating the state’s commitment to Aerospace; all of the reasons which ultimately led Kratos to choose Oklahoma for our new facility.”

“I am pleased to welcome Kratos to Oklahoma. With our skilled workforce and longstanding commitment to supporting our Armed Forces, Oklahoma is an excellent choice for Kratos’ new facility for tactical drone systems,” said U.S. Senator James Inhofe (R-OK). “Kratos, a leader in developing drone technology and producing tactical drone systems to support our military, will create hundreds of high-paying jobs in Oklahoma City and grow our economy.”

“I have been deeply impressed with the incredibly advanced technology Kratos is developing to defend our country and airspace,” said U.S. Rep. Steve Russell (OK). “I have every expectation that Kratos will bring quality, high-paying jobs to the people of our great state, their presence will boost the Oklahoma economy, and most importantly, their work will ensure America has superiority in our airspace for decades to come.”

“Oklahoma is one of the world’s premier destinations for the aerospace and defense industry. Kratos’ announcement of a new facility is a testament to the strength of the industry in our state,” said Oklahoma Governor Mary Fallin. “Our skilled aerospace and engineering workforce combined with the Quality Jobs Program and the Aerospace Engineering Tax Credit incentives along with our proximity to other world-class companies and defense operations made Oklahoma City the right choice for Kratos.”

Kratos will continue target drone production from its existing Sacramento facility, with a significant production ramp up having already begun at that facility, and expected to increase even more over the next 24 months. Oklahoma will be the site for new tactical drone production and excess demand requirements related to target drone production.

Kratos is initially occupying an 8,800 square foot facility in Oklahoma City, not far from Tinker AFB, where the initial focus will be on engineering and production planning. Within six months, the company plans to expand into a 75,000 square foot facility to support its initial production efforts in OK. The company expects to employ more than 350 workers in Oklahoma within the next few years.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops transformative, affordable technology for the Department of Defense and commercial customers. Kratos is changing the way breakthrough technology for these industries are brought to market through proactive research and a streamlined development process. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, training and combat systems. For more information go to www.kratosdefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 25, 2016, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Friday, January 26th, 2018 Uncategorized Comments Off on $KTOS Opens Oklahoma Design and Production Facilities Due to Demand for UAV Drones

$DGLY Confident It Will Prevail in Lawsuit Against Axon Enterprise

Axon Enterprise continues to accrue significant potential damages through sales of infringing products while the case proceeds to trial

Lenexa, KS, Jan. 26, 2018 – Digital Ally, Inc. (NASDAQ:DGLY) today provided an update on the potential damages accruing in its patent infringement lawsuit against Axon Enterprise, Inc. (“Axon,” formerly known as TASER International, Inc.). The lawsuit, filed in the United States District Court of Kansas, accuses Axon of willfully infringing Digital’s U.S. Patent No. 9,253,452 (the “’452 Patent”). The products accused of infringement in this lawsuit cover Axon’s camera products sold with Axon’s Signal functionality, which Digital Ally alleges incorporate its patented auto-activation technology.

Axon has continued to increase its sales of products utilizing Digital’s patented technology while the lawsuit is pending. For example, in 2016 and 2017, Axon’s public filings show $37,848,000 in total net sales of the accused Axon Body and Axon Flex cameras. Net sales of Evidence.com, which drives the sales of the accused products and is sold in conjunction with nearly every camera sale, totaled $69,958,000 in those years.  Finally, Axon’s public filings indicate that “bookings,” which Axon believes to be the best statistical measure of future contractual sales attributable to the company segment responsible for the accused cameras and evidence.com subscriptions, totaled $254,093,000 in 2016 and $219,998,000 in 2017.

In November 2017, the Court rejected Axon’s request to maintain a stay of the litigation and the case is now proceeding towards trial. The measure of Digital Ally’s potential damages may be derived from Axon’s reported sales from the infringing products and Digital will determine and provide a full accounting of the damages owed to it when it submits its expert report on damages.  Digital will be seeking a reasonable royalty applied to the sales of Axon’s products that have been accused of infringement, which it believes will amount to significant monetary damages, as well as an injunction and/or an accounting of damages for future sales. Digital also has alleged that Axon’s infringement has been willful and, as such, Digital is also seeking that any damages awarded by a jury be tripled.

“Axon has continued to build its line of Axon camera products on the back of Digital’s patented auto-activation technology,” said Digital’s CEO, Stanton E. Ross. “It is frustrating to see our technology being used by a competitor to generate such massive sales, but we are confident the jury in Kansas will put an end to this willful infringement and reward Digital for its industry changing auto-activation technology.”

About Digital Ally

Digital Ally, Inc., headquartered in Lenexa, KS, specializes in the design and manufacturing of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: whether the Company will prevail in its patent litigation against Axon Enterprise, Inc.; the amount of any damages that might be awarded to the Company if it is successful in the litigation;  terms of any royalty it may obtain from Axon as a result of the litigation; whether the Company will be able to obtain an injunction against Axon; competition from larger, more established companies with far greater economic and human resources; its ability to attract and retain customers and quality employees; and the effect of changing economic conditions. These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company’s disclosures. It cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements. The reader should consider statements that include the words “believes”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “projects”, “should”, or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking. Digital Ally does not undertake to publicly update or revise forward-looking statements, whether because of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in its annual report on Form 10-K for the year ended December 31, 2016 and quarterly report on Form 10-Q for the three and nine months ended September 30, 2017, as filed with the Securities and Exchange Commission.

Contact Information
Stanton Ross, CEO
Tom Heckman, CFO
Digital Ally, Inc.
913-814-7774
info@digitalallyinc.com
Friday, January 26th, 2018 Uncategorized Comments Off on $DGLY Confident It Will Prevail in Lawsuit Against Axon Enterprise

$IOVA Pricing of Its Public Offering of $150 Million of Common Stock

SAN CARLOS, Calif., Jan. 25, 2018 — Iovance Biotherapeutics, Inc. (Nasdaq:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the pricing of an underwritten public offering of 13,043,479 shares of its common stock at a public offering price of $11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be $150 million. In addition, Iovance has granted the underwriters a 30-day option to purchase up to 1,956,521 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about January 29, 2018, subject to customary closing conditions.

Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund its planned clinical trials for its current product candidates, including a planned Phase 2 clinical trial of LN-145 for the treatment of non-small cell lung cancer (NSCLC), in collaboration with MedImmune, as well as the NSCLC study in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, to fund its planned clinical trials in multiple solid tumor cancers with The University of Texas M.D. Anderson Cancer Center, to fund additional clinical trials to move TIL therapy to an earlier line of treatment, to fund activities related to commercial scale-up of Iovance’s third party manufacturing operations and for working capital and other general corporate purposes.

Jefferies LLC is acting as sole book-running manager for the offering.

The shares of common stock described above are being offered by Iovance pursuant to its shelf registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (the SEC). A preliminary prospectus supplement relating to this offering was filed with the SEC on January 24, 2018. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor New York, New York, 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company’s lead product candidate is an adoptive cell therapy using TIL technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer.

Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding its expectations with respect to its proposed public offering are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering, and the completion of the public offering on the anticipated terms or at all; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the strength of the Company’s product pipeline; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license or development agreements; the acceptance by the market of the Company’s product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. A further list and description of the Company’s risks, uncertainties and other factors can be found in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.iovance.com. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com

Media Relations Contact:
Evan Smith
FTI Consulting
212-850-5622
evan.smith@fticonsulting.com

Thursday, January 25th, 2018 Uncategorized Comments Off on $IOVA Pricing of Its Public Offering of $150 Million of Common Stock

$LTBR and Framatome Launch Enfission to Commercialize Innovative Nuclear Fuel

RESTON, Va., Jan. 25, 2018 – Lightbridge Corporation (NASDAQ:LTBR) (the “Company”), a nuclear fuel technology company, and Framatome, a leader in nuclear fuel, components and reactor services, finalized and launched Enfission, a 50-50 joint venture company to develop, license and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. Lightbridge is a U.S. nuclear fuel development company and Framatome is a leader in designing, building, servicing, and fueling today’s reactor fleet and advancing nuclear energy.

The two companies already began joint fuel development and regulatory licensing work under previously signed agreements initiated in March 2016. The joint venture is a Delaware-based limited liability company.

Bernard Fontana, Chairman of the Managing Board and CEO of Framatome, said, “This is an exciting time of growth for Framatome and we are proud to work with Lightbridge on Enfission. Together, we are developing an innovative fuel technology that will provide significant benefits for our customers, helping them to generate more electricity from their nuclear power plants and better compete in the marketplace. Framatome provides its next generation of fuel assembly designs to more than 100 of the approximately 260 light water reactors worldwide. Through this work, we help our customers to meet their operational goals with a high level of safety. We are confident that our strategic partnership with Lightbridge on Enfission will strengthen our position as a key international player in the global fuel market.”

Seth Grae, Lightbridge president and CEO, said, “With the world calling for more reliable, economic and carbon-free baseload power, Lightbridge’s innovative metallic fuel technology will help both existing and new nuclear plants fill that need. Framatome is the ideal partner with established manufacturing capabilities, an impeccable reputation as a nuclear fuel supplier and a large global footprint. We appreciate the strong support we have already received from the leading nuclear operators, both in the U.S. and around the world. The world’s energy and climate needs can only be met if nuclear power grows as a part of the energy-generating mix. We are honored to work with Framatome on this important project and believe the economic and safety benefits of our fuel will encourage greater use of nuclear power.”

About Framatome

Framatome is a major international player in the nuclear energy market recognized for its innovative solutions and value-added technologies for designing, building, maintaining, and advancing the global nuclear fleet. The company designs, manufactures, and installs components and fuel for nuclear power plants and offers a full range of reactor services.

With 14,000 employees worldwide, every day Framatome’s expertise helps its customers improve the safety and performance of their nuclear plants and achieve their economic and societal goals.

Join the energy conversation with Framatome Inc. on Twitter: @FramatomeUS and Facebook: @FramatomeUS.

Framatome is owned by the EDF Group (75.5%), Mitsubishi Heavy Industries (MHI – 19.5%) and Assystem (5%).

About Lightbridge Corporation

Lightbridge (NASDAQ:LTBR) is a nuclear fuel technology development company based in Reston, Virginia, USA. The Company develops proprietary next generation nuclear fuel technologies for current and future reactors. The technology significantly enhances the economics and safety of nuclear power, operating about 1000° C cooler than standard fuel. Lightbridge invented, patented and has independently validated the technology, including successful demonstration of the fuel in a research reactor with near-term plans to demonstrate the fuel under commercial reactor conditions. The Company has assembled a world class development team including veterans of leading global fuel manufacturers. Four large electric utilities that generate about half the nuclear power in the US already advise Lightbridge on fuel development and deployment. The Company operates under a licensing and royalty model, independently validated and based on the increased power generated by Lightbridge-designed fuel and high ROI for operators of existing and new reactors. The economic benefits are further enhanced by anticipated carbon credits available under the Clean Power Plan. Lightbridge also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at http://ir.ltbridge.com/alerts.cfm .

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

With the exception of historical matters, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the joint venture and its impact on each company’s businesses, customers and positions in the global fuel market; the development of innovative metallic fuel technology; the world’s energy and climate needs; and the ability of commercial nuclear power to meet the world’s energy and climate needs. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to, the degree of market adoption of the Company’s product and service offerings; market competition; dependence on strategic partners; demand for fuel for nuclear reactors; the Company’s ability to manage its business effectively in a rapidly evolving market; as well as other factors described in Lightbridge’s filings with the Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

Investor Relations Contact:

David Waldman/Natalya Rudman
Tel. +1 855-379-9900
ir@ltbridge.com

Thursday, January 25th, 2018 Uncategorized Comments Off on $LTBR and Framatome Launch Enfission to Commercialize Innovative Nuclear Fuel

$ETST NetworkNewsAudio Audio Press Release on Legal Cannabis Industry Diversity

New York, New York–(January 25, 2018) – NetworkNewsAudio announces an Audio Press Release (APR) titled “Diversity Spells Success in the Cannabis Market,” featuring Earth Science Tech, Inc. (OTC Pink: ETST).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

ETST again extended its reach in June 2017 when it entered into a joint venture to launch its wholly owned KannBidoid, Inc. (“KBD”) subsidiary (http://nnw.fm/c6VBH).

Positioned to take advantage of the recreational vape/smoke shop space, each of KBD’s products is formulated with CBD and kanna – a small groundcover plant natively found in southern Africa – sold and distributed in the form of edibles and vapes/e-liquids products.

About Earth Science Tech, Inc.

Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates it is the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. For more information, visit the company’s website at www.EarthScienceTech.com

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, January 25th, 2018 Uncategorized Comments Off on $ETST NetworkNewsAudio Audio Press Release on Legal Cannabis Industry Diversity

$STLHF Sees Arkansas Brine Fields as Potential Lithium Source – NetworkNewsBreaks

January 12, 2018

  • Standard Lithium recently completed option agreement on 33,000-acre lease in longtime commodities-producing region
  • Company expects existing historical data to streamline quick turnaround in resource estimates
  • Lithium exploration gaining popularity as tech industry companies seek to shore up supply lines
  • Recent drilling order announcement clearly puts Administration on side of energy industry

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is exploring the possibility that oil resource-rich Southern Arkansas could become a large source of lithium amid demands for the modern tech commodity.

Since 1920, the Smackover region’s oil fields near the state’s boundary with Louisiana have been a major employer, even though the boom years ended about a decade after the first large discovery. The oilfield brine byproduct was long considered a nuisance, but, in time, it came to be celebrated for chemicals with fire-retardant properties. Following a second round of mineral exploration, Arkansas has become the world’s largest producer of bromine.

A modern need to augment the scarce mineral resources that make up the high-tech, high-efficiency lithium-ion batteries in so many mobile phones and other Internet-connected consumer electronics, as well as electric vehicles, is fueling what could become a game-changing third round of mineral excitement in the region. Automakers and other companies competing in a global marketplace are jostling with each other to secure a steady supply chain well before an actual need for more lithium-ion battery components exists.

Lithium-ion batteries are also significant players in mass storage systems for electrical power grid operators. As the systems look for longer capacity in their storage technology, lithium is expected to remain a key player (http://nnw.fm/A4vFx), particularly as the cost of the batteries continues to fall. However, electric vehicles and governmental demands for ‘clean energy’ are expected to dominate the market for the batteries in the coming decade or more.

Standard Lithium, which considers part of its mission to minimize resource and political risks in its exploration efforts, considers the 33,000 acres of Smackover Formation brine leases it signed an option agreement for this month to be fertile ground, given the area’s long history of brine production; significant existing infrastructure; access to roads, power and water; and the trained workforce in the region, as well as its existing brine extraction, processing and re-injection permitting regime.

“Due to the wealth of already-available data from our new project area, we can start the process of compiling a maiden resource estimate for this large lease package extremely quickly, with a minimum of additional intrusive investigation,” President and COO Andy Robinson stated in a news release about the agreement issued on January 8 (http://nnw.fm/pUf6U).

The existing infrastructure and data would allow Standard Lithium its best chance of quickly adding resources to its assets.

The company states that Arkansas produces the equivalent of 42.6 million cubic meters, or 9.38 billion gallons, of brine per year, based on the Arkansas Oil and Gas Commission’s reported average brine production from between 2010 and 2016. Almost all of those billions of gallons of brine came from the Smackover Formation.

The Smackover Formation itself extends through Texas, Arkansas and Louisiana, and it has produced billions of barrels of brines during the last eight decades from an “extensive and extremely well characterized” aquifer, according to the company’s analysis.

Standard Lithium also has a significant lithium exploration project under way in Southern California’s Mojave Desert. Having a large domestic source for lithium-ion batteries would help satisfy concerns about a secure supply chain in United States markets that currently see half of their lithium supply come from imports. According to the U.S. Geological Survey, the United States reported only 38,000 tons of defined lithium reserves.

“The U.S. has a lot more untapped lithium resources than economically mined reserves at this point,” USGS mineral commodity specialist Brian Jaskula said in a February report (http://nnw.fm/f9L19). In addition, the recent government order opening offshore waters to drilling (http://nnw.fm/oK3kt) is a clear indication of Administration support for the overall tapping of oil resources.

For more information, visit the company’s website at http://nnw.fm/standardlithium

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, January 25th, 2018 Uncategorized Comments Off on $STLHF Sees Arkansas Brine Fields as Potential Lithium Source – NetworkNewsBreaks

$CIIX NetworkNewsAudio Audio Press Release on Crypto and Blockchain

New York, New York–(January 25, 2018) – NetworkNewsAudio announces an Audio Press Release (APR) titled “Established Companies Positioning to Invest in Blockchain and Cryptocurrencies,” featuring ChineseInvestors.com, Inc. (OTCQB: CIIX).

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

“Although there has been some volatility in the cryptocurrency market, Bitcoin’s price resilience is impressive … With each rebound in price relative to news, we see more evidence that the concept of digital currency is taking root with investors and the general public alike,” CEO Warren Wang stated in the press release (http://nnw.fm/mU7QS). “In addition to providing skilled investors with news about digital currency, ChineseInvestors.com, Inc. hopes to satisfy the average person’s curiosity about cryptocurrency, including how to purchase Bitcoin. Moreover, the underlying Blockchain Technology is extremely compelling and we expect to see many interesting developments in this area. Bitcoin ATMs are just one example of how this area is moving forward. We are excited to make this service available to the Chinese community.”

Wang advised industry entrepreneurs to be patient with Chinese investors while they learn about digital wallet management and the processes for trading in bitcoin and other cryptocurrencies. He expressed confidence that China may organize a regulated market for cryptocurrency trading in the future.

About ChineseInvestors.com

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products. For more information visit www.ChineseInvestors.com.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today’s markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Thursday, January 25th, 2018 Uncategorized Comments Off on $CIIX NetworkNewsAudio Audio Press Release on Crypto and Blockchain

$LTBR Received Approval for Key Patent Related To Metallic Nuclear Fuel Assembly

LONDON, UK / January 24, 2018 / Active-Investors.com has just released a free research report on Lightbridge Corp. (NASDAQ: LTBR). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LTBR as the Company’s latest news hit the wire. On January 22, 2018, the nuclear fuel technology Company declared that it has received a notice of allowance from the US Patent and Trademark Office, for a key patent related to its metallic nuclear fuel assembly design. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Lightbridge most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=LTBR

The Patent Extends Lightbridge’s Patent Portfolio Coverage in the US

This patent allowance extends Lightbridge’s patent portfolio coverage in the United States to an entire metallic fuel assembly design for Western-type pressurized water reactors. The design can also be adapted for use in nearly all other power reactors around the world. This particular patent focuses on the fuel assembly design, building on an earlier US patent involving metallic fuel rod design and other US patents for a different variant of the seed-and-blanket fuel assembly design.

Patents Secured by Lightbridge in 2017

  • On October 18, 2017, Lightbridge received a notice of allowance in the People’s Republic of China for key patent relating to its innovative metallic fuel design, which represented the Company’s second patent in China in 2017. The Company received another notice of allowance in China for key patent covering a tri-lobe variant of its extruded metallic fuel rods used in Russian-type VVER reactors in May 2017.

 

  • On October 12, 2017, Lightbridge received notice of allowance from the European Patent Office for an additional patent relating to its innovative metallic fuel design.

 

  • In July 2017, the Company received a notice of allowance from the Korean Intellectual Property Office for a key divisional patent covering two major inventions, Lightbridge’s innovative metallic fuel assembly design for Western-type pressurized water reactors incorporating four-lobe, helically twisted metallic fuel rods, and the Company’s proprietary manufacturing method for metallic fuel rods using powder metallurgy.

Lightbridge Signed Agreements with AREVA to Immediately Advance Fuel Development

On November 15, 2017, Lightbridge and AREVA N.P. signed three binding agreements that allowed the companies to immediately advance development of Lightbridge’s innovative metallic fuel technology and protect all associated intellectual property. Both companies are in the process of finalizing their joint venture, which is expected to launch in Q1 2018. The three agreements included a Research and Development Services Agreement, a Co-Ownership Agreement, and an Intellectual Property Annex. AREVA is a leader in servicing and fueling today’s reactor fleet and advancing the future of nuclear energy.

Metallic Nuclear Fuel Technology

Inherent design features of the Lightbridge metal fuel technology are expected to enhance safety characteristics of nuclear power plants under normal operation and certain off-normal events. The advanced fuel technology is designed to significantly improve the economics, performance, and safety of nuclear power plants

About Lightbridge Corp.

Founded in 1989, Lightbridge is a leading provider of safe and secure nuclear energy consulting services to commercial and governmental entities worldwide, and the company is developing next generation nuclear fuel technology that will increase power output, enhance nuclear power plant economics, and improve used fuel management. The Company is headquartered in Mclean, Virginia.

Stock Performance Snapshot

January 23, 2018 – At Tuesday’s closing bell, Lightbridge’s stock rose 1.29%, ending the trading session at $2.35.

Volume traded for the day: 4.04 million shares, which was above the 3-month average volume of 1.75 million shares.

Stock performance in the last month – up 130.39%; previous three-month period – up 119.63%; past twelve-month period – up 151.34%; and year-to-date – up 92.62%

After yesterday’s close, Lightbridge’s market cap was at $27.33 million.

The stock is part of the Basic Materials sector, categorized under the Synthetics industry.

 

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

 

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

 

Email: info@active-investors.com

 

Phone number: 73 29 92 6381

 

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

 

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Wednesday, January 24th, 2018 Uncategorized Comments Off on $LTBR Received Approval for Key Patent Related To Metallic Nuclear Fuel Assembly

$NETE Releases Letter to Shareholders

Strongest balance sheet in the company’s history to support organic growth and blockchain developments

MIAMI, FL, Jan. 24, 2018 (GLOBE NEWSWIRE) — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (POS), e-commerce, mobile devices and the blockchain ecosystem, today released the following letter to shareholders from the Company’s chief executive officer, Oleg Firer:

Dear Fellow Shareholders,

The global payments industry continued to deliver healthy growth during 2017, with underlying transaction volumes demonstrating even greater strength. Exciting projects and disruptive technologies, like blockchain, will provide us the opportunity to continue developing and delivering innovative payment solutions in 2018 and beyond.

We are poised for growth in 2018 with the strongest balance sheet in our company’s history providing support for executing on opportunities.

During 2017 we continued our organic growth in the U.S. with a focus on value-added payments solutions. We successfully centralized our operations and re-focused our business initiatives internationally.

  • Total transaction dollars processed during 2017 was $2.8 billion
  • Total transaction dollars processed geographically in North American and international markets in 2017 were $2.35 billion and $446 million
  • Transactions processed internationally have seen a 0.38% decline during 2017, due to reorganization and consolidation of the mobile solutions business
  • Growth across all categories was organic

Accomplishments:

  • Received a $7.55 million institutional investment to support continued organic growth and blockchain focused developments
  • Ensured continued compliance with NASDAQ listing requirements
  • Ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™
  • Supported Florida SMB merchants affected by Hurricane Irma with free mobile point of sale credit card readers

Partnerships:

  • Partnered with Elo to provide a modern best-in-class point of sale solution
  • Partnered with Payvision in Europe, extended access to global currencies
  • Partnered with Planet Payment for multi-currency pricing solution in the United States
  • Launched payment acceptance for V-Tell, international mobile network operator
  • Launched payment acceptance for Azimuth Airlines
  • Added support for iDEAL, the most popular payment system in Netherlands

Product launches:

  • Launched same-day ACH payment processing solution in the United States
  • Launched Zero-Fee processing program for SMB merchants in the United States
  • Launched loyalty program for merchants
  • Launched PayOnline’s support for electronic commerce in the United States
  • Launched Apple Pay support in Russia
  • Launched payment acceptance module for Telegram, Viber, Facebook and VK instant messenger apps
  • Expanded payments module to include Prominent InSales
  • Launched comprehensive point-of-sale program during Unified Payments’ “2017 Launch Series” at Northeast Acquirers Association event
  • Launched ISO incubator program for certified resellers of Unified Payments to help them grow their business, compete and achieve success in today’s evolving marketplace

We are very pleased with our 2017 progress and look forward to further significant accomplishments in 2018 to include the addition of blockchain technology that will act as a framework for an unlimited number of value-added services.

Most importantly, we remain focused on the execution of our long-term objective to create a single, international on-boarding and transaction processing platform across payments ecosystems.

On behalf of our entire team, I want to personally thank all of you for your continued support.

Sincerely,

Oleg Firer
Chief Executive Officer
Net Element, Inc.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.netelement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to whether contemplated projects and the utilization of blockchain technology will be successful, whether the addition of blockchain technology-focused business unit will indeed become a framework for multiple value-added services, whether the Company  will be successful in expansion and growth endeavors s; and even if it is successful in any or all of these endeavors, whether this will positively impact the Company or result in improved shareholder value. Additional examples of such risks and uncertainties are : (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Net Element, Inc.
1-786-923-0502
media@netelement.com
Wednesday, January 24th, 2018 Uncategorized Comments Off on $NETE Releases Letter to Shareholders

$ETST NetworkNewsWire Publication on Cannabis Subsectors Offering Investment Avenues

January 23, 2018

NetworkNewsWire Editorial Coverage: For the growing population of investors within the cannabis market, marijuana-related portfolios are frequently designed to be diverse — an advisable investment strategy for any trading portfolio. From the cultivation side of the cannabis sector to biotech/medical/pharmaceutical, ancillary services, cannabis oils, edibles and beyond, the different avenues for marijuana investment are abundant. For companies like Earth Science Tech, Inc. (ETST) (ETST Profile), the existence of diversity within its own operations offers a similar advantage, enabling the company to touch on and benefit from the success of various subsectors within the cannabis market. Though uniquely structured, ETST is paced alongside other cannabis industry players like Insys Therapeutics, Inc. (INSY), Namaste Technologies, Inc. (CSE: N) (OTCMKTS: NXTTF), Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Emerald Health Therapeutics, Inc. (TSX.V: EMH) (OTCQX: EMHTF).

A Diverse Arena

The forward-march of cannabis legalization throughout North America has led to record-breaking growth within this market, and business opportunities have gone far beyond the bud to include assorted products like gourmet marijuana edibles, cannabis-derived oils, cannabis-based pharmaceuticals, health and beauty products, vape pens and smoking accessories, agricultural innovations, payment solutions, and more.

As decriminalization efforts continue worldwide, the cannabis market only grows stronger. A recent Bloomberg report cites Brightfield Group’s prediction that legal cannabis sales will reach $31 billion on a global level by 2021 (http://nnw.fm/Xo0Ts). Like the individual strands in a rope, the diverse subsectors within the cannabis market are twining together to form an increasingly strong whole.

Strength in Variety

For companies like Earth Science Tech, Inc. (OTC: ETST), operating diversified subsidiaries is proving to be favorable path of growth within the cannabis market. The innovative biotech currently has three wholly owned subsidiaries under its umbrella, building an effective tripod of strength for the company. Though these subsidiaries are diverse in nature, their synergy lies in the application of science to the pursuit of optimal health.

Launched in February 2017, the Cannabis Therapeutics, Inc. (“CTI”) subsidiary is purposed to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products. At the core of this mission are Earth Science Tech’s existing cannabis cannabidiol (CBD) patent, IP and future technologies to be developed.

Focused on exploring and harnessing the medicinal power of CBD, CTI’s research and development efforts are geared toward the development of CBD-based drugs and nutraceuticals; and the integration of the CBD molecule with existing generic drug molecules to make drugs more efficient with fewer and less severe side effects.

The subsidiary’s pipeline includes two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products for a variety of ailments, such as anxiety, depression, triple negative breast cancer and fatty liver disease.

CTI positions ETST in the rapidly evolving cannabinoid-based pharmaceuticals market, which Statista projects could reach $50 billion by the year 2029. Meanwhile, a report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021.

Discovering New Revenue Streams

ETST again extended its reach in June 2017 when it entered into a joint venture to launch its wholly owned KannBidoid, Inc. (“KBD”) subsidiary (http://nnw.fm/c6VBH).

Positioned to take advantage of the recreational vape/smoke shop space, each of KBD’s products is formulated with CBD and kanna — a small groundcover plant natively found in southern Africa — sold and distributed in the form of edibles and vapes/e-liquids products.

Rooted Research & Development

Though not centered on cannabis, ETST’s Earth Science Pharmaceutical, Inc. subsidiary represents the core of the company’s R&D capabilities.

Earth Science Pharmaceutical is focused on the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes, and vaccines for sexually transmitted infections (STI) and/or diseases. Its first medical device, MSN-2, is a home detection STI kit being prepared for molecular diagnostics trials.

The subsidiary is managed by an executive team with years of scientific, medical and business experience in health, research and manufacturing. The expertise of this team — headed by ETST CEO and SCO Dr. Michael Aubé and COO Nickolas Tabraue — provides each of ETST’s subsidiaries a multi-dimensional approach to their respective markets.

Strategic Expansion via Acquisition & Partnerships

In 2017 Earth Science Tech also increased operational diversity with the acquisition of Montreal-based Canna Inno Laboratories, which provides ETST access to government grants for up to half of its R&D expenditures.

ETST also has agreements with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), which specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace; and with Brazilian company, Bionatus. Inc. to develop a treatment for asthma (http://nnw.fm/PE43r).

Branded Cannabidiol

Leveraging the strategies of its subsidiaries, ETST continues to raise brand visibility, offering full-spectrum, high-purity hemp-derived CBD oil. In collaboration with the University of Central Oklahoma and the DV Biologics Laboratory, the company is conducting R&D projects designed to scientifically support the health care benefits of its completely natural and organic CBD oil.

Earth Science Tech’s products include CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. They are available at retail stores throughout the United States, as well as online.

The company has also started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.

2017 Performance Points to 2018 Potential

As discussed in a recent article (http://nnw.fm/pd0Md) and year-end review (http://nnw.fm/38VbO), ETST nearly doubled its revenues in 2017 compared with the previous year, and a price target of more than $4 has been set for its stock.

ETST’s achievements in 2017 add weight to Dr. Aubé’s positive forecast for the company’s future.

“This past year has been amazing. I am elated about the start of the New Year given all that we accomplished in 2017. … We have built the foundation and infrastructure the Company needs to succeed long-term … and I feel that we are now on the way to becoming the next billion-dollar (in-capitalization) company on the OTC Markets.”

Comparable Cannabis Players

Insys Therapeutics (INSY) is focused on improving patient care by addressing unmet medical needs through cannabinoids and novel drug delivery systems. The company’s approved products include SYNDROS, a cannabinoid medicine used to treat anorexia in adults with AIDS and to address nausea and vomiting caused by chemotherapy, and SUBSYS, which is used to manage breakthrough pain in adult cancer patients who have become tolerant to opioid therapy.

Namaste Technologies (NXTTF) is an online retailer of medical cannabis delivery systems, distributing vaporizers and smoking accessories worldwide through e-commerce websites in 26 countries and five distribution hubs. Through its 2017 acquisition of CannMart Inc., Namaste is pursuing a new revenue vertical in online medical cannabis retail sales in the Canadian market, with an aim of positioning itself as a retail medical cannabis distribution leader in Canada. During 2018, Namaste intends to establish a secure telemedicine portal that will connect doctors with medical marijuana patients, allowing Canadian patients to receive product recommendations via email and to have their prescriptions filled via postal mail. The company further plans to expand its product offerings in 2017 and to launch a Canadian warehouse in the CannMart facility.

Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company that is focused on developing and commercializing novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Lenabasum is the company’s lead product candidate and is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Emerald Health Therapeutics (EMHTF) is an emerging global cannabis player and, through its wholly owned subsidiary Emerald Health Botanicals Inc., is a licensed producer of medical marijuana in Canada through the Access to Cannabis for Medical Purposes Regulations (ACMPR). The company currently operates an indoor facility in Victoria, B.C., and is in the process of constructing a 500,000-square-foot greenhouse in Metro Vancouver that has expansion potential to 1 million square feet. Emerald additionally owns 50 percent of Pure Sunfarms Inc. (a partnership with Village Farms International Inc.), which is currently converting just under half of its 1.1 million-square-foot greenhouse in Delta, B.C., from a tomato-growing operation into a cannabis-cultivation facility.

Broadening the Landscape

Diversity is advisable for any investment portfolio, and innovative companies like Earth Science Tech are proving diversity’s effectiveness as a business strategy as well. As the global cannabis market continues to gain strength, the above-mentioned companies are positioned to lead the way into the foreseeable green future.

For additional information about Earth Science Tech, visit Earth Science Tech, Inc. (OTC: ETST).

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Wednesday, January 24th, 2018 Uncategorized Comments Off on $ETST NetworkNewsWire Publication on Cannabis Subsectors Offering Investment Avenues

$CERS Positive Top-Line Results, Chronic Anemia Phase 3 INTERCEPT Study

CONCORD, Calif.

  • Study successfully met primary efficacy and safety endpoints
  • No antibodies detected specific to INTERCEPT treated red blood cells
  • No treatment-emergent antibodies to red blood cell alloantigens
  • Conference call scheduled tomorrow at 8:30 am ET, Wednesday January 24

Cerus Corporation (NASDAQ: CERS) today reported that the primary efficacy and safety endpoints were successfully achieved in the company’s Phase 3 transfusion study of chronic anemia evaluating INTERCEPT-treated red blood cells (RBCs) in thalassemia patients, SPARC (A Randomized Controlled Study to Evaluate Efficacy and Safety of S-303 Treated Red Blood Cells in Subjects with Thalassemia Major Requiring Chronic RBC Transfusion). The results from the SPARC study provide important clinical data regarding the safety profile of INTERCEPT-treated RBCs in a chronically transfused patient population and support Cerus’ INTERCEPT RBC CE mark submission, which is planned for the second half of 2018.

The study’s primary efficacy endpoint used a non-inferiority design to assess up to a 15% relative difference in the mean consumption of hemoglobin between INTERCEPT-treated RBC and conventional RBC. The safety endpoints included the incidence of treatment-emergent antibody with confirmed specificity to INTERCEPT-treated RBCs, the incidence of antibodies to red blood cell alloantigens, the incidence of adverse events, and the incidence of transfusion reactions.

A total of 86 patients were enrolled at three participating international sites in the double blinded, cross-over study. Subjects were randomly assigned to a sequential treatment period of either INTERCEPT-treated RBCs or conventional RBCs with cross over to the other treatment upon completion of the first treatment period. Each treatment period consisted of 6 transfusion episodes. A total of 2006 units were transfused during the course of the study, with 999 in the Control arm and 1007 in the Test arm. Full results of the study are planned for submission and presentation at upcoming scientific conferences and for publication.

“These study results mark a major milestone in our mission to make INTERCEPT the standard of care in transfusion medicine. Thalassemia major patients require a lifetime of red cell transfusion, putting these individuals at elevated risk of transfusion transmitted infections (TTI) from existing and emerging pathogens. We believe that the INTERCEPT Blood System has the potential to markedly reduce the risk of TTI for patients needing red cell transfusions,” said Richard Benjamin, Cerus’ chief medical officer.

In addition to the SPARC study in thalassemia patients, the company’s planned 2018 CE mark submission also will include previously reported clinical results from the company’s successful European Phase 3 study in patients with acute anemia. In the U.S., the company is conducting a Phase 3 study of INTERCEPT-treated RBCs (RedeS) in Puerto Rico and the mainland to ameliorate the risk of Zika virus, and is preparing to initiate a separate Phase 3 study of INTERCEPT-treated RBCs with 600 patients undergoing complex cardiovascular surgery (ReCePI) to support a potential Premarket Approval application (PMA) submission to the FDA for the INTERCEPT Blood System for RBCs.

CONFERENCE CALL INFORMATION

Cerus will host a conference call and webcast tomorrow, January 24 at 8:30 AM ET to discuss the top-line results from SPARC, a Phase 3 study evaluating the safety and efficacy of INTERCEPT treated red blood cells in thalassemia patients.

To access the live webcast, please visit the Investor Relations page of the company’s website at http://www.cerus.com/ir. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international).

A replay will be available on the company’s website, or by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and entering conference ID number 4961559. The replay will be available approximately three hours after the call through February 7, 2018.

ABOUT THALASSEMIA

Thalassemia is a genetic blood disorder caused by a defect in synthesis of hemoglobin, the oxygen-carrying component of the red blood cell. Insufficient production of hemoglobin results in severe chronic anemia leading to multiple organ dysfunction unless treated with transfusion support. Thalassemia major is the most severe form of the disease and symptoms may present in patients as early as 6-months old. Patients with thalassemia major may require a lifetime of transfusions. Thalassemia is more common in individuals from Mediterranean countries, Asia, Africa, and the Middle East.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements concerning Cerus‘ planned INTERCEPT red blood cell CE Mark submission and the timing thereof; Cerus’ mission to make INTERCEPT the standard of care in transfusion medicine; Cerus’ belief that the INTERCEPT Blood System has the potential to markedly reduce the risk of TTI; Cerus’ planned Phase 3 ReCePI study; the potential submission of a PMA to the FDA by Cerus for the INTERCEPT Blood System for RBCs; and other statements that are not historical facts. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the uncertain and time-consuming development and regulatory process, including the risks (a) that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe on the anticipated timeframe or at all, and even if filed, Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all, (b) that applicable regulatory authorities may disagree with Cerus‘ interpretations of the data from its clinical studies and/or may otherwise determine not to approve Cerus‘ regualtory submissions in a timely manner or at all; (c) that anticipated clinical trials of the INTERCEPT Blood System may not be initiated on the ancticipated timing or at all, or if initiated, may be extended, delayed, suspended or terminated, including as result of safety concerns, and (d) that negative or inconclusive results in Cerus‘ Phase 3 studies of INTERCEPT RBCs, including in the RedeS or the ReCePI studies would negatively impact, substantially delay or preclude altogether, Cerus‘ ability to submit a PMA to the FDA for INTERCEPT Blood System for RBCs and Cerus‘ ability to obtain regulatory approval of the INTERCEPT Blood System for RBCs in the United States, and that Cerus may otherwise be unable to submit a PMA to the FDA for the INTERCEPT Blood System for RBCs in a timely manner or at all; risks related to Cerus‘ need for additional funding; risks future opportunities and plans, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, filed with the SEC on November 3, 2017. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

 

Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations Director
or
Media Contact:
W20 Communications
Dan Boyle
dan@boylepr.com

Tuesday, January 23rd, 2018 Uncategorized Comments Off on $CERS Positive Top-Line Results, Chronic Anemia Phase 3 INTERCEPT Study

$STLHF Announces $20 Million Bought Deal Private Placement of Units

VANCOUVER, Jan. 23, 2018 – Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) announced today that it has entered into an agreement with Canaccord Genuity Corp., as sole bookrunner and lead underwriter on behalf of a syndicate of underwriters (the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal, private placement basis, 9,530,000 units of the Company (the “Units”), at a price of $2.10 per Unit (the “Offering Price”) for aggregate gross proceeds of $20 million (the “Offering”).

The Company has also granted the Underwriters an option (the “Underwriters’ Option”) to purchase up to an additional 1,429,500 Units at the Offering Price, exercisable in whole or in part at any time for a period of 48 hours prior to the closing of the Offering. If the Underwriters’ Option is exercised in full, the aggregate gross proceeds of the Offering will be $23 million.

Each Unit will be comprised of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 24 months following the closing of the Offering at an exercise price of $2.60 per Warrant Share. Net proceeds from the Offering will be used for exploration and development activities on the Company’s properties and for general corporate purposes.

All securities issued or issuable under the Offering will be subject to a statutory hold period lasting four months and one day following the closing of the Offering.

Closing of the Offering is expected to occur on or about February 13, 2018. The Offering is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange.

About Standard Lithium Ltd.

Standard Lithium’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to approximately 33,000 acres of brine leases located in the Smackover Formation.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

On behalf of the Board,

Standard Lithium Ltd.
Robert Mintak, CEO & Director

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated closing date of the Offering, the anticipated use of proceeds of the Offering, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

Tuesday, January 23rd, 2018 Uncategorized Comments Off on $STLHF Announces $20 Million Bought Deal Private Placement of Units

$NETE SeeThruEquity Launches Blockchain and Cryptocurrency Research and Advisory Practice

NEW YORK, NY / January 23, 2017 / SeeThruEquity, the leading independent equity research firm for publicly traded emerging growth companies, announced today that it is launching its Blockchain and Cryptocurrency Practice to serve clients in these exciting new markets.

SeeThruEquity has been an early mover in the space, launching research coverage of many of the leading names in the industry, including:

India Globalization Capital, Inc. (NYSE: IGC)
LongFin Corp. (NASDAQ: LFIN)
Long Blockchain Corp. (NASDAQ: LTEA)
Net Element, Inc. (NASDAQ: NETE)
Social Reality, Inc. (NASDAQ: SRAX)
ZK International Group Co., Ltd. (NASDAQ: ZKIN)
IEG Holdings Corp. (OTCQB: IEGH)
MassRoots, Inc. (OTCQB: MSRT)

The firm also plans on initiating coverage on numerous new companies in the near future. The reports on these companies and SeeThru’s entire coverage universe can be found on SeeThru’s website HERE.

As a result, SeeThruEquity has developed a significant knowledge base and network of contacts including investors, service providers and technologists in the blockchain and cryptocurrency markets which it may utilize in providing research and advisory services for companies that are in these markets or seek to enter them.

Blockchain and cryptocurrency, including BitCoin, have received a lot of attention in the media in 2017 as public awareness has intensified, but we believe this is only the very early phase of the growth in these markets. As continuing and widespread adoption of these technologies increases, SeeThruEquity is uniquely positioned to serve the needs of companies that seek to leverage these technologies.

SeeThruEquity has long been an innovator in the equity research space with the most unique business model in the equity research industry which is focused on getting research coverage to emerging growth companies which historically have faced a challenge in attracting the attention of the old world, institutional providers of equity research, and as a result, has grown its coverage universe to over 230 companies since its founding in 2011.

“We will harness our nimbleness in disrupting the existing equity research marketplace to deliver value to companies in this fast moving and explosive growth sector of blockchain and cryptocurrencies. We believe no one else has the coverage of as many companies in the space as we do, and we intend to lead the pack as the sector grows and matures,” commented Ajay Tandon, CEO of SeeThruEquity.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information about the new practice please contact SeeThruEquity at (646) 495-0939 or info@seethruequity.com. The corporate website can be found at www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

Tuesday, January 23rd, 2018 Uncategorized Comments Off on $NETE SeeThruEquity Launches Blockchain and Cryptocurrency Research and Advisory Practice

$CIIX Established Companies Positioning to Invest in Blockchain and Cryptocurrencies

January 23, 2018

NetworkNewsWire Editorial Coverage: Despite the skepticism in the market about the legitimacy and longevity of bitcoin and other cryptocurrencies, the underlying blockchain technology is something that tech firms and the financial sector cannot ignore. While cryptocurrencies’ surging values and wild price fluctuations have made many established organizations reluctant to invest in this market, Bloomberg reports that Goldman Sachs is setting up a trading desk for cryptocurrencies (http://nnw.fm/ayFK8). This positions the company to be the first large Wall Street investment banker to trade in digital currency. Businesses such as ChineseInvestors.com, Inc. (CIIX) (CIIX Profile) are taking advantage of the deeper rooted blockchain market that seems to offer infinite application. Xunlei Limited (XNET), a cloud-based computing company, is another company extending its reach by incorporating blockchain technology in its offerings, and still others showing interest in the cryptocurrency, bitcoin and blockchain sector include MGT Capital Investments, Inc. (MGTI), Riot Blockchain, Inc. (RIOT) and the retailer Overstock.com, Inc. (OSTK).

The number of corporate investors in blockchain companies hit a record high in 2017, with large banks and financial service organizations leading the way. Among the growing list of recognizable names, Google’s parent company, Alphabet Inc. (NASDAQ: GOOG), is another big investor in blockchain (http://nnw.fm/guBC3). Increased application and acceptance are subsequently pushing the value of cryptocurrencies, the tokens used in blockchain technology, higher. In 2017, they surged to $600 billion from just over $18 billion at the start of the year (http://nnw.fm/wVAZ0).

Additionally, initial coin offerings (ICOs) are overtaking traditional funding options for blockchain start-ups. Several huge deals were negotiated during 2017, including the $107 million raised by R3, a company developing a blockchain database for use by global financial institutions. Coinbase, a digital currency exchange based in San Francisco, raised $100 million in equity funding.

Committed to Cryptocurrency

ChineseInvestors.com, Inc. (CIIX) was founded in 1999 and has developed into a leading financial website for Chinese-speaking investors in China and the United States. The company’s clients trade in the OTCQB Venture Market, NASDAQ and NYSE public markets, among others. With a core focus on investor education, the site offers various products and services such as real-time market analysis, commentary and investment education. The company also offers advice to smaller companies on growth strategy, while providing support services for advertising and public relations.

ChineseInvestors.com saw its first-quarter investor relations (IR) revenues grow 186 percent over comparable revenues reported in the first quarter of 2017. During the 2017 fiscal year, the company’s IR sales made a 130-percent, year-over-year leap to $808,362 (http://nnw.fm/53Ge6). ChineseInvestors.com is becoming more selective about its client companies in the process, and is entering into more cash compensation arrangements. Now it proposes to extend its educational coverage to bitcoin and the cryptocurrency market.

The company has stated its commitment to the future of bitcoin and other cryptocurrencies, and has thus decided to spin off its wholly owned cannabis subsidiaries (CBD Biotechnology Co., Ltd. and ChineseHempOil.com) to focus efforts on its new cryptocurrency division. Despite China’s ban on cryptocurrency trading on domestic regulated exchanges, company CEO Warren Wang remains highly optimistic about the future of bitcoin and other cryptocurrencies, noting that Chinese investors are bypassing the ban to trade on unregulated offline platforms.

In an interview with the Bad Crypto Podcast, Wang said: “The Chinese investor is an advocate of gambling. Most today trade bitcoin and other cryptocurrencies on the offline market. The Chinese-speaking people within China and also in North America — the U.S. and Canada — are excited about bitcoin.”

Cryptocurrency also provides investors the ability to diversify their portfolio and shift away from traditional investment opportunities.

“Real estate is very expensive and so are labor and rents in China. Investors have a high savings rate. They now would like to make bitcoin and other cryptocurrencies part of their assets. They are trading offline on platforms of decentralized exchanges to do so,” Wang explained.

With a strong commitment to cryptocurrency education and awareness, ChineseInvestors.com broadcasts a daily video, called Bitcoin MultiMillionaire, from the NYSE. The company also hosts and has installed a Bitcoin ATM in the lobby of its headquarters in San Gabriel, California. This installation enables the company to reach the Chinese-speaking community worldwide with bitcoin marketing, even though Chinese regulators have banned sales of bitcoin.

“Although there has been some volatility in the cryptocurrency market, Bitcoin’s price resilience is impressive … With each rebound in price relative to news, we see more evidence that the concept of digital currency is taking root with investors and the general public alike,” Wang stated in the press release (http://nnw.fm/mU7QS). “In addition to providing skilled investors with news about digital currency, ChineseInvestors.com, Inc. hopes to satisfy the average person’s curiosity about cryptocurrency, including how to purchase Bitcoin. Moreover, the underlying Blockchain Technology is extremely compelling and we expect to see many interesting developments in this area. Bitcoin ATMs are just one example of how this area is moving forward. We are excited to make this service available to the Chinese community.”

Wang advised industry entrepreneurs to be patient with Chinese investors while they learn about digital wallet management and the processes for trading in bitcoin and other cryptocurrencies. He expressed confidence that China may organize a regulated market for cryptocurrency trading in the future.

Comparable Companies

Multinational technology company Xunlei Limited (XNET) is an online service provider investing in cryptocurrency from its base in Shenzhen, China. The company’s cloud-based platform enables users to access, manage and consume digital media content. Its Xunlei Accelerator product enables users to accelerate digital transmission over the internet through various products, such as Green Channel and Offline Accelerator. Mobile Xunlei allows users to search, download and consume media content on mobile devices. Xunlei’s OneThingCloud is a LinkToken mining platform designed to be mobile-compatible for digital currency mining. Mid-October 2017, the company launched OneCoin, a cryptocurrency that has experienced a dramatic increase in value, more than 80-fold since launch.

MGT Capital Investments (MGTI) focuses on acquiring and developing a portfolio of cyber security technologies. The company also addresses various cyber threats through the implementation of protection technologies for mobile and personal devices, as well as corporate computer networks. MGT is also actively engaged in bitcoin mining. In December 2017 the company announced its agreements to secure reliable and adequate electric power in Sweden and that it expects to start deployment of mining rigs early in 2018. The initial phase of the agreement will provide MGT with 25 megawatts of power, enough for more than 15,000 Bitmain S-9 mining rigs.

Originally known as Bioptix Pharma, Riot Blockchain (RIOT) has experienced rapid growth following its decision to reorient its focus from biopharmaceuticals to blockchain technology. The company’s stock soared from $7 in November 2017 to over $46 in mid-December. Riot Blockchain’s mission is to establish itself as an authority on blockchain technology, while offering investors valuable exposure to the blockchain market. The company invested in Verady, LLC, which provides accounting and auditing services to the digital currency market. It also owns a share in Coinsquare, a Canadian-based cryptocurrency exchange. Riot Blockchain has majority ownership of TessPay, a blockchain-based payment resource for wholesale telecom carriers.

Overstock.com (OSTK) is a U.S.-based online, award-winning retailer, which, through its Medici Ventures INC subsidiary, is also focused on blockchain applications with the potential to disrupt industries such as capital markets, finance and banking, property registration and voting identity verification. Medici recently raised over $2.2 million in a seed funding round for mobile voting platform, Voatz, which aim to use blockchain technology and biometrics improve voting infrastructure security (http://nnw.fm/4nqGD).

Many companies are concerned about the volatility in the cryptocurrency market. However, there is increasing acceptance that blockchain technology is here to stay and will continue to have a growing impact on the way the world transacts and does business. These companies are taking the lead by positioning themselves to capitalize on this opportunity and develop their enterprises as leaders in this industry.

For more information on ChineseInvestors.com, please visit: ChineseInvestors.com (CIIX)

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, January 23rd, 2018 Uncategorized Comments Off on $CIIX Established Companies Positioning to Invest in Blockchain and Cryptocurrencies

$ETST Diversity Spells Success in the Cannabis Market

January 23, 2018

NetworkNewsWire Editorial Coverage: For the growing population of investors within the cannabis market, marijuana-related portfolios are frequently designed to be diverse — an advisable investment strategy for any trading portfolio. From the cultivation side of the cannabis sector to biotech/medical/pharmaceutical, ancillary services, cannabis oils, edibles and beyond, the different avenues for marijuana investment are abundant. For companies like Earth Science Tech, Inc. (ETST) (ETST Profile), the existence of diversity within its own operations offers a similar advantage, enabling the company to touch on and benefit from the success of various subsectors within the cannabis market. Though uniquely structured, ETST is paced alongside other cannabis industry players like Insys Therapeutics, Inc. (INSY), Namaste Technologies, Inc. (CSE: N) (OTCMKTS: NXTTF), Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Emerald Health Therapeutics, Inc. (TSX.V: EMH) (OTCQX: EMHTF).

A Diverse Arena

The forward-march of cannabis legalization throughout North America has led to record-breaking growth within this market, and business opportunities have gone far beyond the bud to include assorted products like gourmet marijuana edibles, cannabis-derived oils, cannabis-based pharmaceuticals, health and beauty products, vape pens and smoking accessories, agricultural innovations, payment solutions, and more.

As decriminalization efforts continue worldwide, the cannabis market only grows stronger. A recent Bloomberg report cites Brightfield Group’s prediction that legal cannabis sales will reach $31 billion on a global level by 2021 (http://nnw.fm/Xo0Ts). Like the individual strands in a rope, the diverse subsectors within the cannabis market are twining together to form an increasingly strong whole.

Strength in Variety

For companies like Earth Science Tech, Inc. (OTC: ETST), operating diversified subsidiaries is proving to be favorable path of growth within the cannabis market. The innovative biotech currently has three wholly owned subsidiaries under its umbrella, building an effective tripod of strength for the company. Though these subsidiaries are diverse in nature, their synergy lies in the application of science to the pursuit of optimal health.

Launched in February 2017, the Cannabis Therapeutics, Inc. (“CTI”) subsidiary is purposed to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products. At the core of this mission are Earth Science Tech’s existing cannabis cannabidiol (CBD) patent, IP and future technologies to be developed.

Focused on exploring and harnessing the medicinal power of CBD, CTI’s research and development efforts are geared toward the development of CBD-based drugs and nutraceuticals; and the integration of the CBD molecule with existing generic drug molecules to make drugs more efficient with fewer and less severe side effects.

The subsidiary’s pipeline includes two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products for a variety of ailments, such as anxiety, depression, triple negative breast cancer and fatty liver disease.

CTI positions ETST in the rapidly evolving cannabinoid-based pharmaceuticals market, which Statista projects could reach $50 billion by the year 2029. Meanwhile, a report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021.

Discovering New Revenue Streams

ETST again extended its reach in June 2017 when it entered into a joint venture to launch its wholly owned KannBidoid, Inc. (“KBD”) subsidiary (http://nnw.fm/c6VBH).

Positioned to take advantage of the recreational vape/smoke shop space, each of KBD’s products is formulated with CBD and kanna — a small groundcover plant natively found in southern Africa — sold and distributed in the form of edibles and vapes/e-liquids products.

Rooted Research & Development

Though not centered on cannabis, ETST’s Earth Science Pharmaceutical, Inc. subsidiary represents the core of the company’s R&D capabilities.

Earth Science Pharmaceutical is focused on the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes, and vaccines for sexually transmitted infections (STI) and/or diseases. Its first medical device, MSN-2, is a home detection STI kit being prepared for molecular diagnostics trials.

The subsidiary is managed by an executive team with years of scientific, medical and business experience in health, research and manufacturing. The expertise of this team — headed by ETST CEO and SCO Dr. Michael Aubé and COO Nickolas Tabraue — provides each of ETST’s subsidiaries a multi-dimensional approach to their respective markets.

Strategic Expansion via Acquisition & Partnerships

In 2017 Earth Science Tech also increased operational diversity with the acquisition of Montreal-based Canna Inno Laboratories, which provides ETST access to government grants for up to half of its R&D expenditures.

ETST also has agreements with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), which specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace; and with Brazilian company, Bionatus. Inc. to develop a treatment for asthma (http://nnw.fm/PE43r).

Branded Cannabidiol

Leveraging the strategies of its subsidiaries, ETST continues to raise brand visibility, offering full-spectrum, high-purity hemp-derived CBD oil. In collaboration with the University of Central Oklahoma and the DV Biologics Laboratory, the company is conducting R&D projects designed to scientifically support the health care benefits of its completely natural and organic CBD oil.

Earth Science Tech’s products include CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. They are available at retail stores throughout the United States, as well as online.

The company has also started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.

2017 Performance Points to 2018 Potential

As discussed in a recent article (http://nnw.fm/pd0Md) and year-end review (http://nnw.fm/38VbO), ETST nearly doubled its revenues in 2017 compared with the previous year, and a price target of more than $4 has been set for its stock.

ETST’s achievements in 2017 add weight to Dr. Aubé’s positive forecast for the company’s future.

“This past year has been amazing. I am elated about the start of the New Year given all that we accomplished in 2017. … We have built the foundation and infrastructure the Company needs to succeed long-term … and I feel that we are now on the way to becoming the next billion-dollar (in-capitalization) company on the OTC Markets.”

Comparable Cannabis Players

Insys Therapeutics (INSY) is focused on improving patient care by addressing unmet medical needs through cannabinoids and novel drug delivery systems. The company’s approved products include SYNDROS, a cannabinoid medicine used to treat anorexia in adults with AIDS and to address nausea and vomiting caused by chemotherapy, and SUBSYS, which is used to manage breakthrough pain in adult cancer patients who have become tolerant to opioid therapy.

Namaste Technologies (NXTTF) is an online retailer of medical cannabis delivery systems, distributing vaporizers and smoking accessories worldwide through e-commerce websites in 26 countries and five distribution hubs. Through its 2017 acquisition of CannMart Inc., Namaste is pursuing a new revenue vertical in online medical cannabis retail sales in the Canadian market, with an aim of positioning itself as a retail medical cannabis distribution leader in Canada. During 2018, Namaste intends to establish a secure telemedicine portal that will connect doctors with medical marijuana patients, allowing Canadian patients to receive product recommendations via email and to have their prescriptions filled via postal mail. The company further plans to expand its product offerings in 2017 and to launch a Canadian warehouse in the CannMart facility.

Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company that is focused on developing and commercializing novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Lenabasum is the company’s lead product candidate and is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Emerald Health Therapeutics (EMHTF) is an emerging global cannabis player and, through its wholly owned subsidiary Emerald Health Botanicals Inc., is a licensed producer of medical marijuana in Canada through the Access to Cannabis for Medical Purposes Regulations (ACMPR). The company currently operates an indoor facility in Victoria, B.C., and is in the process of constructing a 500,000-square-foot greenhouse in Metro Vancouver that has expansion potential to 1 million square feet. Emerald additionally owns 50 percent of Pure Sunfarms Inc. (a partnership with Village Farms International Inc.), which is currently converting just under half of its 1.1 million-square-foot greenhouse in Delta, B.C., from a tomato-growing operation into a cannabis-cultivation facility.

Broadening the Landscape

Diversity is advisable for any investment portfolio, and innovative companies like Earth Science Tech are proving diversity’s effectiveness as a business strategy as well. As the global cannabis market continues to gain strength, the above-mentioned companies are positioned to lead the way into the foreseeable green future.

For additional information about Earth Science Tech, visit Earth Science Tech, Inc. (OTC: ETST).

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Tuesday, January 23rd, 2018 Uncategorized Comments Off on $ETST Diversity Spells Success in the Cannabis Market

$LTBR Receives U.S. Approval for Key Patent for its Innovative Fuel Design

Expands patents around fuel assembly design with initial focus on pressurized water reactors

RESTON, Va. , Jan. 22, 2018 — Lightbridge Corporation (NASDAQ:LTBR), a nuclear fuel technology company, today announced it has received a notice of allowance for a key patent from the U.S. Patent and Trademark Office related to its metallic nuclear fuel assembly design. Lightbridge’s advanced fuel technology is designed to significantly improve the economics, performance and safety of nuclear power plants.

This latest patent allowance extends Lightbridge’s patent portfolio coverage in the United States to an entire metallic fuel assembly design for Western-type pressurized water reactors, which comprise two-thirds of those in operation worldwide. However, Lightbridge’s metallic fuel designs can also be adapted for use in nearly all other power reactors around the world.

Lightbridge President and CEO Seth Grae said: “This latest notice for a U.S. patent further expands the broad global patent protection already surrounding our fuel.  This particular patent focuses on the fuel assembly design, building on an earlier US patent involving metallic fuel rod design and other US patents for a different variant of the seed-and-blanket fuel assembly design.  The intellectual property in our proprietary fuel designs reflects years of research and tireless effort by our team, including many of the leading experts within the nuclear energy field.”

Over the past year, Lightbridge has secured patents in China, South Korea and the European Union related to its innovative advanced fuel design. The company is in the process of finalizing a joint venture with Framatome, a leader in nuclear fuel, components and reactor services, to further develop and commercialize metallic fuel for nuclear plants around the world.

About Lightbridge Corporation

Lightbridge (NASDAQ:LTBR) is a nuclear fuel technology development company based in Reston, Virginia, USA. The Company develops proprietary next generation nuclear fuel technologies for current and future reactors. The technology significantly enhances the economics and safety of nuclear power, operating about 1000° C cooler than standard fuel. Lightbridge invented, patented and has independently validated the technology, including successful demonstration of the fuel in a research reactor with near-term plans to demonstrate the fuel under commercial reactor conditions. The Company has assembled a world class development team including veterans of leading global fuel manufacturers. Four large electric utilities that generate about half the nuclear power in the US already advise Lightbridge on fuel development and deployment. The Company operates under a licensing and royalty model, independently validated and based on the increased power generated by Lightbridge-designed fuel and high ROI for operators of existing and new reactors. The economic benefits are further enhanced by anticipated carbon credits available under the Clean Power Plan. Lightbridge also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at http://ir.ltbridge.com/alerts.cfm .

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Investor Relations Contact:
David Waldman/Natalya Rudman
Tel. +1 855-379-9900
ir@ltbridge.com

Monday, January 22nd, 2018 Uncategorized Comments Off on $LTBR Receives U.S. Approval for Key Patent for its Innovative Fuel Design

$CIIX Sees Bright Future for Cryptocurrencies in China

January 22, 2018

  • Warren Wang, CEO of CIIX, says trading is active for cryptocurrencies in China on over-the-counter exchanges
  • CIIX doubles down on its commitment to bitcoin and other cryptocurrencies, spinning off two other corporate divisions to spend more time on building its new cryptocurrency division
  • The company’s goal is to gain revenue, profitability and value for its shareholders

ChineseInvestors.com, Inc. (OTCQB: CIIX) sees a bright future for cryptocurrencies in China due to interest among Chinese investors in making cryptocurrencies part of their portfolios of assets (http://nnw.fm/8eAv8). Warren Wang, CEO of CIIX, said in a news release that the emerging middle class in China is expressing its desire to be educated about trading and investing in bitcoin and other cryptocurrencies.

CIIX, as a result, is doubling down on its commitment to bitcoin growth by offering a real-time daily video broadcast from the NYSE, targeted at the Chinese-speaking community in China and North America. The broadcast’s goal is to educate viewers on the latest cryptocurrency news. The company also hosts a bitcoin ATM in the lobby of its San Gabriel, California, headquarters.

Wang, in a recent interview on The Bad Crypto Podcast (http://nnw.fm/5LImO), said that Chinese investors are selling and buying cryptocurrencies through unregulated, over-the-counter exchanges, because conventional exchanges are banned by the government from trading in cryptocurrencies. These investors, he said, are persistent in their desire to trade the volatile cryptocurrency. Wang stressed that the Chinese community is motivated by the growth of bitcoin and other cryptocurrencies.

CIIX is a diverse company serving the Chinese-speaking community. It has recently spun off two of its corporate divisions that were involved in hemp marketing and the legal cannabis industry to focus, instead, on the education and marketing of bitcoin and other cryptocurrencies.

“There’s so many cryptocurrencies from China emerging, or at least on the exchange right now,” he said in the interview. He added that there is tremendous opportunity for CIIX to bring added revenue and profitability to its shareholders as the Chinese investment community seeks education about the volatile market of bitcoin and other cryptocurrencies. He urged entrepreneurs to be patient as this large community takes time to learn more about this market.

For more information, visit the company’s website at www.ChineseInvestors.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, January 22nd, 2018 Uncategorized Comments Off on $CIIX Sees Bright Future for Cryptocurrencies in China

$IGC Engages CFN Media to Develop New Investor Audience

SEATTLE, WA, Jan. 22, 2018  — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced that India Globalization Capital Inc. (NYSE: IGC) has engaged CFN Media to conduct a 3-month investor and market visibility program to begin on January 22, 2018.

“India Globalization Capital has developed a patent-pending cannabis-based combination therapy to treat patients with Alzheimer’s disease,” said Frank Lane, President of CFN Media. “The company plans to market its cannabis-based combination therapy to medical dispensaries and clinics in the United States and Canada this year. In addition to these near-term programs, the company is working on leveraging its experience to develop blockchain technology based solutions for the burgeoning cannabis industry.”

CFN Media will leverage its powerful content platform and extensive reach to mainstream and cannabis-focused investors and media across North America to attract high-quality investors to India Globalization Capital Inc. while elevating the company’s financial brand.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to the worldwide cannabis industry, helps marijuana companies attract investors, customers (B2B, B2C), capital, and publicity. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

The company launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

About India Globalization Capital Inc.

IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA).  The Company is based in Maryland, USA.

For more information please visit www.igcinc.us and www.igcpharma.com

 

CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com
Monday, January 22nd, 2018 Uncategorized Comments Off on $IGC Engages CFN Media to Develop New Investor Audience

$NCNA Promising Clinical Data at ASCO GI on NUC-1031 in Biliary Tract Cancer

NuCana Planning to Initiate a Phase 3 Study of Acelarin in Front-Line Advanced Biliary Tract Cancer

EDINBURGH, United Kingdom, Jan. 19, 2018 — NuCana plc (NASDAQ:NCNA) announced interim results today from the ABC-08 Study at the 2018 ASCO Gastrointestinal Cancer Symposium (ASCO GI) in San Francisco, CA.  This analysis of the Phase 1b multi-center, open-label study showed that Acelarin, when combined with cisplatin, achieved high response rates and was well-tolerated in front-line advanced biliary tract cancer.

Eight patients with advanced biliary tract cancer received Acelarin (625mg/m2) and cisplatin (25mg/m2) on days one and eight of a three-week cycle.  A Complete Radiological Response was achieved in one patient, a Partial Response in three patients, and Stable Disease in one patient, resulting in an Objective Response Rate of 50% and a Disease Control Rate of 63% on an intent-to-treat basis.  Additionally, the one patient with Stable Disease, whose cancer initially had been considered unsuitable for surgical resection, went on to have surgery to remove the tumor completely.  Two of the eight patients received only one cycle or less of therapy due to complications unrelated to either Acelarin or cisplatin, so the Objective Response Rate in those patients who received adequate treatment was 67%.

“Although this is only an interim analysis in a small number of patients, these data are very encouraging and suggest that the combination of Acelarin and cisplatin could represent a significant advance in the treatment of advanced biliary tract cancer, a devastating disease for which there are no approved medicines,” remarked Professor Juan Valle, Co-Chief Investigator of the ABC-08 Study and Professor and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie, Manchester, United Kingdom.

Dr. Mairéad McNamara, Co-Chief Investigator of the ABC-08 Study and Senior Lecturer and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie, added, “In addition to the high response rate, it was noteworthy that this combination achieved a Complete Response and the patient with Stable Disease went on to have surgical resection. Both outcomes are very uncommon in this setting.”

Additionally, the combination of Acelarin and cisplatin was well-tolerated with no unexpected adverse events and no dose-limiting toxicities.

Based on the high response rates and favorable safety profile seen in cohort 1, the Trial Management Group determined that Acelarin at 625mg/m2 with cisplatin at 25mg/m2 was the optimal combination.  Professor Valle and his co-investigators had previously established the current standard of care for the front-line treatment of patients with advanced biliary tract cancer in the ABC-02 study that was published in the New England Journal of Medicine in 2010.  Professor Valle added, “Since ABC-02, there have not been any studies that have demonstrated an improvement in overall survival in the front-line treatment of patients with advanced biliary tract cancer; there is an urgent need for new therapies for our patients.”

A comparison of the data from the ABC-08 and ABC-02 studies is provided in the following table:


Objective Response Rates in ABC-08 and ABC-02
ABC-08 ABC-021
NUC-1031 + cisplatin
625 mg/m2 + 25 mg/m2
gemcitabine + cisplatin
1000 mg/m2 + 25 mg/m2
Complete Response 13% (1/8) 0.6% (1/161)
Partial Response 38% (3/8) 25.5% (41/161)
Objective Response Rate 50% (4/8) 26.1% (42/161)
  1. Valle et al. N Engl J Med 2010; 363:1273-1281

Hugh S. Griffith, NuCana’s Chief Executive Officer, said: “We are excited by the exceptional results achieved so early in this study.  Consistent with our strategy of rapidly advancing our new medicines in multiple cancer types, and based on the results of this study, we plan to initiate a pivotal study of Acelarin and cisplatin in front-line advanced biliary tract cancer in 2018.”

About NuCana plc

NuCana® is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Our most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies for patients with ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is currently in a Phase 1 study for the potential treatment of a wide range of advanced solid tumors.

For more information, please visit: www.nucana.com.

Forward-Looking Statements

This press release may contain “forward‐looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the “Company”). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the initiation, timing, progress and results of clinical studies of the Company’s product candidates. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our prospectus filed pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933, as amended, on September 29, 2017, and subsequent reports that we file with the U.S. Securities and Exchange Commission.  Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

Hugh S. Griffith
Chief Executive Officer
+44 131 357 1111
info@nucana.com

Westwicke Partners
Chris Brinzey
+1 339-970-2843
Chris.brinzey@westwicke.com

RooneyPartners
Marion Janic
+1 212-223-4017
mjanic@rooneyco.com

Friday, January 19th, 2018 Uncategorized Comments Off on $NCNA Promising Clinical Data at ASCO GI on NUC-1031 in Biliary Tract Cancer
Top Small Cap Market News